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      Irritable bowel syndrome (IBS) is a chronic disorder with symptoms of 
abdominal pain, discomfort or bloating associated with alterations in bowel habits 
without organic disease. Bloating is a troublesome and poorly understood 
symptom in IBS. It has been suggested that impaired gut motility and altered 
sensitivity may be the mechanism of bloating. We thus hypothesized that 1) 
bloating predominant IBS patients in Asia have delayed intestinal transit; and 2) 
tegaserod could improve bloating and intestine transit in these patients. Therefore, 
the objective of this study is to investigate the symptomatology of bloating, the 
role of gastrointestinal transit and effect of tegaserod in non-diarrhea IBS patients 
with bloating.  
 
      In the first part of this thesis, the symptoms profiles of non-diarrhea IBS 
patients with bloating were assessed. It was showed that there were more common 
complaints with upper abdominal bloating associated with moderate bowel 
disturbance in these patients. Using psychological questionnaires, these IBS 
patients were observed to have higher HAD scores than healthy controls. 
Additionally, the results of IBS education survey suggested that more IBS health 
education and health-care costs about IBS should be provided to Asian patients.  
 
 vi
       The second part of this thesis was to investigate the gastrointestinal transit in 
non-diarrhea IBS patients with bloating and normal controls, using 
radioscintigraphic method. The results showed these bloating IBS patients had 
significant slower small bowel transit than normal controls. However, there were 
no significant differences in the gastric emptying half-time and ileocaecal transit 
times between the IBS patients and normal controls. Meanwhile, it was found that 
majority of these IBS patients and none of the normal controls reported bloating 
during the scan.  
 
       In the third part of this thesis, the effect of 5-HT4 receptor agonist Tegaserod 
was investigated in a randomized, double blind and controlled study.  Compared 
with placebo, administration of oral tegaserod 6mg twice a day for two weeks 
significantly alleviated bloating symptom in non-diarrhea IBS patients with 
bloating. It was also showed partial improvement in bowel habits after tegaserod 
treatment. On the other hand, tegaserod accelerates small bowel transit time 
without any effect on gastric emptying and ileocaecal transit time. Moreover, the 
improvement of bloating score is positively correlated to the decrease of small 
bowel transit time in tegaserod group.  
 
      In conclusion, we demonstrated that non-diarrhea IBS patients with bloating in 
Asia presented with upper abdominal bloating, moderate bowel disturbance and 
 vii
higher HAD scores than normal controls. Moreover, these patients have impaired 
small intestinal transit. Tegaserod 6 mg b.i.d alleviated the bloating symptoms and 
bowel disturbance. In addition, tegaserod significantly accelerated small bowel 
transit in bloating predominant IBS patients compared with placebo. The findings 
suggested that tegaserod could provide effective treatment for non-diarrhea IBS 




















       Chapter 1   
   










1.1 Irritable Bowel Syndrome (IBS) 
1.1.1     Overview 
      Irritable bowel syndrome (IBS) is a chronic disorder with symptoms of 
abdominal pain, discomfort or bloating associated with alterations in stool 
frequency and/or consistency and the absence of detectable organic disease. IBS is 
a very common functional bowel disorder, which are markedly influenced by 
psychological factors and life style. Although not life threatening, it is one of the 
major diagnoses in outpatient clinic and the most frequent reason for consultation 
with a gastroenterologist (Harvey, 1983; Drossman, 1997). It is clear that 
symptoms that are suggestive of IBS are common, however only a quarter of these 
symptomatic patients seek medical advice for their symptoms (Drossman et al, 
1992). Despite this, it is estimated that IBS is responsible for approximately 2.4 to 
3.5 million physician visits per year and represents 12% of primary care visits and 
28% of referrals to gastroenterologists (Sandler et al, 1990). In Singapore, a study 
revealed that IBS makes up 17% of new referrals to a tertiary gastroenterology 
centre (Kang et al. 1994). 
 
       Since there is no biological marker that can identify patients with this disorder, 
IBS traditionally is viewed as a diagnosis of exclusion to making a positive 
diagnosis based on standard criteria. The diagnosis of IBS is based on 
characteristic symptoms and several symptom-based criteria for IBS have been 
developed to facilitate and standardize its diagnosis (Somers et al, 2003). 
According to the bowel pattern, it is divided to three types of IBS: constipation-
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predominant IBS (C-IBS), diarrhea-predominant IBS (D-IBS), and alternating IBS 
(A-IBS). 
 
        IBS substantially impairs the quality of life (QOL) of affected individuals. 
The QOL in patients who have IBS is worse than that of the general population 
and is similar to that of patients who have any of several significant medical 
conditions (Gralnek et al, 2000). Patients with IBS have 2 to 3 times work 
absenteeism than other employees (Drossman et al, 1993), and the health care 
costs entailed in caring for IBS patients is 1.6 times that of other patients (Talley 
et al, 1998). Moreover, IBS patients are more likely to exhibit health care-seeking 
behaviors that are related to gastrointestinal and non-gastrointestinal complaints. 
The annual economic consequences of IBS are substantial. It was estimated that 
IBS accounts for approximately $1.7 to $10 billion in annual direct medical costs 
per year in United States (Cash et al, 2004).  Due to limited understanding of this 
disorder and lack of gold standard for diagnosis, irritable bowel syndrome is 
certainly an important research area. Therefore it gains increasing attention and 
interests from clinicians, researchers and pharmaceutical industry.  
 
1.1.2 Epidemiology 
      IBS epidemiology varies from different definition. The recent Rome I and 
Rome II criteria are more restrictive than the earlier Manning criteria. IBS 
prevalence and gender distribution are different between the west and Asia 
(Cremonini et al, 2005). In West the prevalence of IBS in the community is 
reported to be 10%-20% (Sandler et al, 1990). A community survey using the 
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Manning criteria showed that IBS affected 22% of the British population aged 
between 20 to 90 years. Another study using the same criteria, found the 
prevalence was 17% in a different age group (30-64 years) (Talley et al, 1991). 
IBS symptoms were found in 9.4% of the United States population by Rome 
criteria (Drossman et al, 1993). In the U.S. Householder Survey (Drossman et al, 
1993), IBS was present in 14.5% of women but in only 7.7% of men. Similar 
gender disparity was shown in other studies from western country which reported 
IBS affected females approximately twice as often as males (Jones et al, 1992; 
Heaton et al, 1992). 
 
      The prevalence rates in Asian studies have been generally lower than in the 
west. The female :male ratio across Asian studies is around 1.5:1 (Cremonini et al, 
2004)  Actually, a study on urban populations in China report rates similar to 
those observed in the west (Xiong et al, 2004). It is found that the prevalence is 
less than 5% in Thailand (Danivat et al, 1988). In Singapore, a population-based 
cross-sectional survey conducted by a team from the National University of 
Singapore (Gwee et al, 2004), where 2,276 people were interviewed in their 
homes, IBS was found to affect about 1 in 10 people. Women between 20 and 40 
years of age had the highest frequency (16%) and men aged 50 years and above 
had the lowest (5%). However, an early study reported that 81% of IBS patients 
were male (Bordie, 1972). There are differences between western and eastern 
countries in disease epidemiology. In addition, IBS seems to be more common in 
younger age groups. It was founded that only about 10% of IBS patients are 
between 60-70 years old (Harvey et al, 1987).  
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1.1.3  Diagnosis of IBS 
      It is very important to make a correct diagnosis of IBS since it reassures 
patients about the prognosis of their disease and provide a therapeutic strategy on 
controlling their symptoms, such as pain/bloating, constipation, diarrhea. The 
differential diagnosis in patients with symptoms that are suggestive of IBS is 
broad. IBS has historically been viewed as a diagnosis of symptom-based rather 
than as a primary diagnosis. However, for a variety of reasons, the diagnosis of 
IBS is not an easy task compared with other organic diseases. First of all, 
clinicians are not confident to use positive symptom criteria to detect IBS which 
implies IBS remains a diagnosis of exclusion. Secondly, with the lack of a 
biological marker, symptoms of IBS patients are not specific for the syndrome and 
are characterized by a significant inter-and intra-individual variability (De Giorgio 
et al, 2004). 
 
      IBS patients can be classified by their predominant symptom and by their stool 
frequency, stool form, and stool passage. Accordingly, IBS may be constipation-
predominant, diarrhea-predominant, or alternating at varying times. This 
classification will help practitioners to plan a diagnostic and therapeutic strategy 
(Ringel et al, review 2001).   
 
1.1.3.1 Diagnosis criteria  
      Over the past decades, several groups have developed symptom-based criteria 
to help researchers and physicians in identifying patients with IBS. In 1978 
Manning et al were the first to describe six key abdominal/intestinal symptoms, 
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now referred to as 'Manning criteria', to help the diagnosis of IBS. Those symptom 
criteria distinguish patients with IBS from those with organic intestinal diseases 
(Manning et al, 1978) (Table 1-1). Kruis et al added other criteria, including a 
requirement for symptoms to have been present for more than two years and the 
use of symptom complexes that increase the chances of making a positive clinical 
diagnosis (Kruis et al, 1984). Rome I and more recent Rome II (Table1-1), 
developed by multinational research groups, provide a uniform framework for the 
selection of patients in diagnostic and therapeutic trials of IBS.  
 
      In recent years, the application of these criteria to patients in clinical practice 
has been encouraged. Studies found that the Rome II criteria are specific for IBS 
and have the advantage of being easier to recall and use than the older Manning or 
Rome I criteria (Drossman et al, 2002). However, recent evidence suggests the 
Rome II may not be as sensitive as the Rome I criteria, mainly because of the 
more restrictive temporal pain requirement that is associated with Rome II 
(Vanner et al, 1999; Chey et al, 2002). This means that patients fulfilled with IBS 
criteria are likely to suffer from IBS, while those patients who do not fulfill the 
criteria still ultimately end up with a diagnosis of IBS (Cash, 2004). Overall, the 







Table 1-1.     Symptom-based criteria so far established for the diagnosis of IBS  
Manning 
  Pain relieved by defecation 
  More frequent stools at the onset of pain 
  Looser stools at the onset of pain 
  Visible abdominal distension 
  Passage of mucus 
  Feeling of incomplete evacuation 
Rome I 
  Abdominal pain or discomfort for at least 3 months with at least 1 of the 
   following symptoms: 
    relieved with defecation 
    associated with change in frequency of stools 
  Associated with change in form of stools and two or more of the 
 following symptoms: 
    altered stool frequency and/or form 
    altered stool passage 
    passage of mucus 
    bloating or abdominal distension 
Rome II 
 Abdominal pain or discomfort for at least 12 weeks in 12 months with at 
 least two of the following symptoms: 
    relieved with defecation 
    associated with change in frequency of stools 
  Associated with change in form of stools with the following symptoms 
supporting irritable bowel syndrome: 
    altered stool frequency and/or form 
    altered stool passage 
    passage of mucus 




1.1.3.2 Diagnostic Strategy 
Clinical presentation 
      The predominant symptom of IBS is abdominal pain/ discomfort associated 
with a change in stool frequency or consistency. IBS patients generally experience 
relief from the abdominal pain following defecation. They often have problems 
passing motion with strain, incomplete feeling or urgency. The most frequent 
presentation of IBS is abdominal pain or discomfort accompanied by a change in 
stool frequency, passage and mucus in the stool (Hahn et al, 1997). IBS symptoms 
are likely to be aggravated by stress, alcohol, or food (Bennett et al, 1998). 
Additionally, IBS patients suffering from psychosocial problems may have more 
severe IBS symptoms, more frequent health care seeking, and lower health status 
and poorer clinical outcome than those without psychosocial disturbance 
(Drossman et al, 2000). 
Physical examination 
      IBS patients generally appear to be healthy in physical examination, which 
reveal no evidence of organic disease. Although patients with IBS often have 
tenderness in the left lower abdomen, over the sigmoid colon, and discomfort 
during a digital rectal examination, these findings are neither specific nor sensitive 
enough to be helpful in making the diagnosis of IBS (Fielding, 1981). It is also 
necessary to exclude other medical disorders with similar clinical presentation. 
For example, the anorectal examination should exclude abnormalities in the anal 
and rectal region and evaluate the functioning of the pelvic floor muscles. Also, 
there are certain symptoms should be viewed as alert signs or "red flags," since 
their presence can suggest a diagnosis other than IBS and require further 
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evaluation. These include symptoms that awaken the patient from sleep, first 
presentation at an older age, GI bleeding, weight loss, and fever. 
Diagnostic testing 
      Some recent studies have clearly demonstrated that it is unnecessary to apply 
extensive diagnostic tests in the evaluation of patients with IBS symptoms without 
“red flags”. The initial evaluation could also include the following limited 
diagnostic screening tests: complete blood count; a test of sedimentation rate; 
Thyroid-stimulating hormone; Ova and parasites in patients with diarrhea; flexible 
sigmoidoscopy and screening for occult blood in stool for those less than 50 years 
old; colonoscopy for those greater that 50 years of age (Somers et al, review, 
2003). 
 
      Furthermore, if the initial evaluation shows no signs of organic disorder, the 
physician should start symptomatic treatment and the clinical conditions should be 
reevaluated within 4-6 weeks. If symptoms make a change or if red flags appear, 
further diagnostic tests should be warranted. Additional diagnostic test are usually 
based on the predominant clinical symptoms-constipation, diarrhea, pain or 
bloating (Drossman et al, 1997).  Figure 1-1 summarizes the approach to the 
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                                 Patient with suspected IBS  
       
 





                             Assess for presence of alarm features: 
History                                                                                        
Age≧50; Unintentional weight loss; Family history of GI malignancy; 
Severe unrelenting large volume diarrhea; Fevers, chills, recent travel to  
endemic region; Nocturnal symptoms; Hematochezia  
Physical exam 
Relevant findings (arthritis, skin abnormalities, lymphadenopathy, 
abdominal mass)
Alarm feature                                                                            Alarm feature  




      
                         No improvement 
 
  
                                                                                                         Improvement 
      
            
Directed diagnostic 
               testing 
Make a confident diagnosis of IBS and 
initiate therapy based on predominant 
symptoms 
Follow up in 4-6 weeks 
Continue current therapy 
 
  Figure 1-1. Evidence-based approach to the diagnosis of IBS (Adapt from Cash 





1.1.4 Pathophysiology of IBS  
       The pathophysiology of irritable bowel syndrome still remains unknown, 
although a variety of postulated mechanisms has been developed as the basis of 
IBS for the past decades. It is likely that the IBS represents the expression of 
multiple potential pathophysiology factors, which are dysmotility, visceral 
hypersensitivity, psychological factors, stress, and abnormal brain-gut responses, 
as well as other mechanisms that remain to be elucidated. 
 
1.1.4.1 Altered motility 
      For many years, researchers focused on the role of abnormal motility in the 
pathogenesis of IBS. A number of motor abnormalities have been described in the 
colon and small intestine of IBS patients. Patients with predominant symptom of 
diarrhea seem to have accelerated whole gut and colonic transit times. Conversely, 
decreased transit was revealed in patients who have constipation predominant IBS 
(Cann et al, 1983). Intestinal transit studies suggest that the transit of food through 
the ileocaecal region may be associated with pain and bloating (Cann et al, 1983; 
Trotman et al, 1986). Recently, a study found that IBS patients has impaired 
transit and tolerance to intestinal gas and this has been cited as a possible 
mechanism for bloating which commonly experienced in IBS patients(Serra et al, 
2001).  Similarly study demonstrated that rectal distension accelerates gas transit 
in healthy subjects, however, it fails in IBS patients with bloating which impairs 
their ability to propel and evacuate intestinal gas (Harder et al, 2004). 
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      Moreover, abnormal motility patterns have also been found in other regions of 
the gastrointestinal tract in IBS patients compared with normal controls (Kellow 
and Phillips, 1987). A study found that episodes of pain were associated with 
irregular contractile activity in jejunum (Thompson et al, 1979). Another group of 
researchers recorded bursts of irregular contractile activity and a reduction I 
migrating motor complexes in jejunal motility recordings of IBS and these were 
associated with the occurrence of symptoms (Kumar& Wingate, 1985).  
 
      However, the described qualitative motility changes lack of specificity. 
Differences between IBS patients and healthy subjects more probably reflect a 
quantitative rather than qualitative abnormality (Barbara et al, 2004). Hence, 
abnormal motility is generally not considered to be the only cause of IBS and 
other mechanisms could also be included. 
 
1.1.4.2 Visceral Hypersensitivity  
          Ritchie first investigated that patients had poor tolerance to balloon 
distension of the rectum (Ritchie et al, 1973). After that, decreased sensory 
threshold to rectal distension in IBS patients has been described by several 
research groups. Increased perception of visceral stimuli also affects other regions 
of the gastrointestinal tract, including the sigmoid colon (Delvaux et al, 1999), 
ileum (Kellow et al, 1988), duodenum (Accarino et al, 1995) and oesophagus 
(Trimble et al, 1995). This lower sensation threshold is likely more frequently in 
the diarrhea-predominant IBS group of patients as opposed to the constipation-
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predominant group, in whom discomfort may be perceived at greater distension 
volumes than healthy subjects (Prior et al, 1990).  
 
      Meanwhile, several studies revealed that the hypersensitivity is relatively 
specific for the viscera. Whitehead et al described that IBS patients have normal 
or even increased thresholds for painful stimulation of somatic neuroreceptors 
(Whitehead et al, 1990&1994). In a similar study, IBS patients were found to have 
higher tolerance and pain thresholds to electrocutaneous stimulation than normal 
controls (Cook et al, 1987). Additionally, IBS patients often feel extra-intestinal 
symptoms including headaches, chest pain, fatigue, breathlessness, dysuria and 
dyspaneuria (Whorwell et al, 1986; Talley et al, 1991; Jones et al, 1992).The 
frequency and variety of symptoms suggest that IBS patients may have lower 
sensory threshold and have a tendency to perceive pain and/or other symptoms.  
 
      The mechanisms for visceral hypersensitivity are completely uncertain. It has 
been proposed that multiple factors (genetic, inflammation, motility, local nerve 
mechanical irritation, psychological factors) change neuroreceptor and afferent 
spinal neurone function and CNS modulation. It may occur as a result of the 
recruitment of high threshold silent spinal nociceptors, which downregulate the 
central processing of afferent signals (Cervero et al, 1992). In addition, the 
increased synaptic activity at the spinal level may lead to a change in the 
excitability of dorsal horn projection neurons. So, even when the peripheral 
irritation is reduced, the spinal afferents continue to have a pain memory that 
amplifies stimuli that is perceived as painful. Finally, dorsal horn neurons are 
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subject to CNS modulation and a loss of descending inhibitory modulation could 
further amplify visceral sensation (Drossman, review, 1999).  
 
1.1.4.3 Psychopathology 
      Over the years of research, psychological factors still represents a main field 
of investigation in IBS. Recent study revealed psychosocial and behavioral factors 
play a crucial role in IBS patients (Drossman et al, 2000). Also, psychological 
factors were suggested to predict the development of IBS after an episode of acute 
gastroenteritis in previously asymptomatic individuals (Gwee et al, 1999). 
Numerous studies indicate that IBS patients have greater psychological 
disturbances than healthy subjects. Patients with IBS are found to have higher 
scores for anxiety, depression, hostile feelings, sadness, interpersonal sensitivity 
as well as more sleep disturbance compared with healthy controls (Whitehead et al, 
1980; Svedlund et al, 1985; Gomborone et al, 1995; Ford et al, 1987). Although 
some IBS patients may not meet diagnostic criteria for psychiatric disorders, many 
suffer from psychological distress. As a chronic, functional disorder, IBS could be 
associated with changed in mood, especially depression and anxiety. Furthermore, 
psychiatric comorbidity and impaired psychosocial adjustment are more common 
among IBS patients than among healthy controls and higher rates of IBS are found 
with psychiatric diagnoses (Fullwood et al, 1995). Many patients with IBS have 
counterproductive coping styles, such as cognitions that "catastrophize" symptoms 
and life events (Drossman et al, 2000). On the other hand, psychological factors 
affect digestive motor and visceral perception (Welgan et al, 1988). 
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      Although psychological factors certainly affect to status of IBS symptoms, 
they are unlikely the causes of IBS. In fact, patients with IBS who do not see 
physicians are psychologically similar to normal subjects. Conversely, frequent 
clinic attenders have greater psychosocial disturbances (Smith et al, 1990). IBS 
patients report considerably more disability and work absenteeism than normal 
subjects (Drossman, 1993).These data indicate that psychosocial difficulties may 
influence illness behaviour, fear of cancer, less coping capability and the clinical 
outcome. These behaviours are manifest as increased pain reporting, physician 
visits, the seeking of alternative medical treatment, and even unnecessary surgery 
(Drossman, 1999).  
 
      Having IBS or other chronic illness, has psychosocial consequences on one’s 
quality of life. So, the model is that psychosocial factors can change/aggravate 
clinical symptoms such as pain, bowel movement, and conversely, the chronic 
discomforting and disabling symptoms can affects the patients’ psychological 
status (further anxiety and depression). Hence, a potentially “vicious circle” could 
be used to explain the worsening IBS symptoms and psychological disturbance 
(Barbara et al, review, 2004). 
 
1.1.4.4 Stress 
      The role of stress and stressful event is well recognized in functional GI 
disorders. Psychological stress is widely believed to play a major role in IBS, by 
precipitating exacerbation of symptoms. Studies investigating the stress in healthy 
subjects and experimental animals have clearly demonstrated that psychological 
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and physical stress may induce alterations in GI motility, which in turn could 
cause abdominal symptoms and altered bowel habits (Monnikes et al, 2001). 
Gorard et al found that acute stresses promoted abnormal motility of the small 
intestines in IBS patients, which were different from healthy controls (Gorard & 
Farthing, 1994). Several studies reported that disorder bowel function and colonic 
motility are associated with stress (Almy et al, 1957; Drossman et al, 1977). 
Furthermore, an increased colonic motor response to various psychological (e.g., 
fear, strobe test, mental arithmetic) and physical (e.g. ice water and cold pressure 
tests) stressors in IBS patients compared with normal controls was investigated in 
several research groups (Narducci et al,1985; Welgan et al, 1988;  Fukudo et al, 
1993 ). In contrast, no difference was found in esophageal and intestinal motility 
between IBS patients and healthy controls (Ayres et al, 1989; Kellow et al, 1992). 
Meanwhile, anger stress also inhibits antral motility in IBS patients, which was 
not observed in controls (Welgan et al, 2000). Therefore, it is suggested that the 
colonic motor response to stress is exaggerated in IBS. This idea is in agreement 
with results of electroencephalograms (EEG) studies suggestive of an exaggerated 
responsiveness of the brain and the colon to stress in IBS (Nomura et al, 1999). A 
recent study has also revealed that chronic stress is highly prevalent in IBS and the 
intensity of chronic life stress is significantly associated with the severity and 
extent of gastrointestinal and/ or extra-intestinal symptoms in IBS patients 
(Bennette et al, 1998).     
 
      However, the mechanisms underlying the correlation between stress and gut 
are so far not well understood. Stress, defined as an acute threat to the homeostasis 
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of an organism, real (physical) or perceived (psychological) and posed by events 
in the outside world or from within, evokes adaptive responses which serve to 
defend the stability of the internal environment and to assure the survival of the 
organism (Mayer et al, review, 2001). Numerous reports provided evidence for a 
prominent role of stress in the pathophysiology and in the clinical presentation of 
IBS symptoms. A model has been created to summarize the possible role of 
different types of stressors in the development and modulation of IBS symptoms 
(Fig 1-2). According to this model, a variety of stressors play a role in 1) 
permanent enhancement of stress responsiveness (pathological stress); 2) transient 
symptoms exacerbation; and 3) symptom perpetuation (symptom-generated stress) 












Figure 1-2. Role of stress in development and modulation of IBS symptoms. 





1.1.4.5 The brain-gut interaction 
      Brain-gut interactions are increasingly recognized as underlying mechanisms 
of IBS. Bidirectional communication between the central nervous system (CNS) 
and the enteric nervous system (ENS) occurs both in health and disease. IBS is a 
dysregulation of brain-gut interactions that affect intestinal as well as central and 
peripheral neurological function, mediated through neuroendocrine and 
neuroimmunological pathways (Ringel et al, 2001). The brain-gut axis is 
stimulated by various CNS- and gut- directed stressors. Extrinsic (vision, smell, 
etc.) or enteroceptive (emotion, thought) sources of information have the 
capability to affect gastrointestinal sensation, motility and secretion. Conversely, 
nociceptive input reciprocally affects central pain perception, mood and behaviour 
(Drossman, review, 1999). In IBS, dysregulation has two components. 1) There 
may be dysregulation of motor nerves regulating GI smooth muscle contraction, 
resulting in abnormal intestinal motility. 2) There may be dysregulation of the 
sensory nerves linking intestinal receptors and nerve endings to CNS, resulting in 
enhanced awareness and hypersensitivity to abdominal distension, contraction, 
and discomfort (Mach, review, 2004 & Drossmand et al, 2002). Symptoms 
(abdominal pain, altered motility or bowel habits) in IBS patients can derive from 
dysregulation of activity in one or more of the stations in the bidirectional 
communication pathways between the GI system (ENS) and the spinal cord and 
brain (CNS). 
 
      Researchers have emphasized on study of the role of brain-gut axis. A study 
investigated that spontaneously induced contractions of the colon in rat leads to 
 18
activation of the locus coeruleus in the pons, an area closely connected to pain and 
emotional centers in the brain (Svensson, 1987). Moreover, some imaging studies 
of regional central blood flow during rectal distention suggest the importance of 
altered brain perception of visceral stimuli (Schwetz et al, 2003). Similarly, a 
study using functional brain imaging demonstrated an increased activation of the 
anterior cingulated cortex (ACC) in IBS patients compared to healthy controls. 
This increased brain activation occurs both during actual painful stimuli applied to 
the colon and anticipation of such painful stumuli (Silverman et al, 1997).  
 
      Neural transmission within the gut (ENS) and brain (CNS) is controlled by 
numerous neurotransmitters and neuromodulatory peptides, which including 
corticotrophin releasing factor (CRF), vasoactive intestinal peptide (VIP), 
serotonin, calcitonin gene-related polypeptide (CGRP), acetylcholine, substance P, 
nitric oxide, cholecystokinin, and the enkephalins. (Kirkup et al, 2001). In 
particular, serotonin (5-HT) is a major messenger in the GI tract. Two of 5-HT 
receptors, 5-HT3 and 5-HT4 appear to play an important role in the control of GI 
function (See later Chapter). In past years, the results of a variety of different 
experimental approaches and clinical investigations have shown evidence to the 
organization, neurochemistry and physiology of the brain-gut axis. A better 
understanding of the brain-gut interactions in near future will help the 
development of IBS research.  
 
      In summary, a multi component model that reflects the complexes of IBS has 
been proposed to synthesize the factors discussed above (Figure 1-3). The 
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combined effects of altered physiology and psychosocial status through the brain-
gut axis affect how the symptoms are experienced, the individual’s illness 
behavior, and ultimately the outcome. The clinical outcome, in turn, influences the 
severity of the disorder. This model also provides the basis for the 





Figure 1-3. Conceptual model for irritable bowel syndrome (adapt from Ringel et al, 
2001)     
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1.1.5 Treatment  
      There is no single consistently successful therapeutic approach for IBS 
patients. Since IBS is a chronic disorder, the goals of treatment should focus on 
patient reassurance, education about the syndrome, and symptom improvement, 
rather than on disease cure. The treatment strategy includes non-pharmacological 
and pharmacological approach. 
1.1.5.1 Non-pharmacological therapies 
Dietary therapy 
      Most IBS patients believe that certain foods exacerbate their symptoms. Food 
diaries are recommended because they may help patients identify and avoid 
dietary triggers, which include caffeine, citrus, corn, dairy lactose, wheat, etc. For 
example, diets deficient in fiber may help to explain constipation. Diets containing 
excessive amounts of gas-producing foods (beans, cabbage, legumes, etc), poorly 
absorbed carbohydrates or lactose in patients who are lactose intolerant may 
explain excessive flatus, bloating, or diarrhea. Diets consisting of large fatty meals 
or caffeine may help explain postprandial rectal urgency and bowel frequency 
(Somers& Lembo, 2003). If a patient suggests a significant correlation between a 
particular food and symptoms, then offending food should be eliminated from the 
diet to determine if there is resolution in symptoms. Increasing dietary fiber has 
long been thought as one of the most common recommendations in constipation-
predominant IBS. The proposed mechanism is its ability to reduce the transit time 
of the entire alimentary tract and intestinal wall tension by decreasing intracolonic 
pressure (Muller, 1988). However, the ability of dietary fiber to alleviate 
abdominal pain and diarrhea has been disappointing. It seems that IBS patients 
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with diarrhea-predominant symptoms have greatest number of adverse food 
reactions. Simple dietary advice is inexpensive and harmless and may result in a 
reduction in symptoms in a subset of IBS patients. Moreover, simple life style 
modifications such as exercise and defecating patterns may help individual 
patients.  
Psychotherapy  
      It seems that psychological factors play a significant role in IBS 
manifestations. Several psychological treatments have been used in patients with 
IBS. These include cognitive-behavioral therapy, dynamic/interpersonal 
psychotherapy, hypnotherapy, and stress management training (Guthrie et al, 
1993). The psychotherapeutic approach emphasizes the importance of identifying 
patients’ special concerns, beliefs, and illness perceptions and understanding the 
interaction between physiological and psychosocial factors. Several well-designed 
studies suggest a beneficial effect of psychological treatment in IBS. A 
randomized, controlled trial of IBS patients with long-standing symptoms and no 
response to conventional medical treatment found psychotherapy superior to 
medical treatment in reducing bowel symptoms( diarrhea and abdominal pain), 
psychological symptoms (anxiety and depression), and number of physician visit 
(Drossman et al, 2000). Nevertheless, no single psychological treatment was 
found to be superior. Psychotherapies may be considered for motivated patients 
who have more severe or disabling symptoms (Hadley & Gaarder, 2005) However, 
the clinical response to psychotherapy is limited. Not every patient profits from 
this intervention (Villanueva et al, 2001).  
 
 22
1.1.5.2 Pharmacologic treatment  
      The pharmacological treatment of IBS is aimed at controlling the dominant 
symptom, i.e. constipation, diarrhea and pain/bloating (Camilleri et al, 
2002).Patients should be informed to take any prescribed compound during 
symptom recurrence rather than chronically. The following sections briefly review 
the main classes of drugs in IBS treatment. 
Antidiarrhoeals 
      Loperamide is the most widely used drug for diarrhea-predominant IBS. It is a 
synthetic opioid, obtained from the basis of meperidine, with no effect on the 
central nervous system. Loperamide increases water and ion absorption, decrease 
intestinal transit time and increases anal sphincter tone (Viera et al, 2002). Several 
clinical trials showed that loperamide significantly ameliorates diarrhea, urgency 
and faecal soiling, although it has no effect on other IBS-related symptoms such 
as pain and bloating (Jailwala et al, 2000& Read et al, 1982). Compared to 
codeine and diphenoxylate, loperamide does not cross the blood-brain barrier and 
this feature makes it a relatively safe drug employed extensively in general 
practice. However, loperamide should not be used chronically to avoid rebound 
constipation and its best prescription is as-needed medication during exacerbation 
of diarrhea (De Giorgio et al, 2004). 
Antispasmodics 
      Antispasmodics are thought to relieve IBS symptoms by decreasing strong 
contractions or spasms in the gastrointestinal tract, which are associated with pain.  
Antispasmodics can be classified into three major subclasses: 1) anticholinergics 2) 
peppermint oil 3) direct smooth muscle relaxants. Antispasmodics are indicated in 
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IBS as these patients have increased postprandial colonic motility, which often 
manifests with diarrhea and cramp-like abdominal pain (De Giorgio et al, 2004). 
According to two recent meta-analyses, the overall effect of these compounds is 
superior to placebo in relieving global symptoms and pain, although they had no 
effect on diarrhea and constipation (Jailwala et al, 2000& Poynard et al, 2001). 
Antispasmodics, taken about 30 minutes before meals, can be effective in 
controlling postprandial cramps and diarrhea and they should be recommended for 
this specific therapeutic target. 
 
Serotonergic Agents 
      In recent years, serotonin was found to be an important neurotransmitter in the 
enteric nervous systems, spinal cord, and brain. Specifically, serotonin type-3 (5-
HT3) receptors and serotonin type-4 (5-HT4) receptors that are found on visceral 
sensory neurons and within the nervous system play an important, integrated role 
in the reflexes that control GI sensation, motility, and secretion (Gershon, 1999).  
5-HT3 Receptor antagonists 
      Antagonism of serotonin receptor subtype 5-hydroxytryptamine-3 (5-HT3) 
reduces noxious stimuli perception, increases colonic compliance, and decreases 
gastrocolonic reflexes. Alosetron (Lotronex), the first IBS-specific medication 
approved by the U.S. Food and Drug Administration (FDA), is a highly selective 
central penetrating 5-HT3 antagonist. It is for the treatment of diarrhea-
predominant IBS in female patients resistant to conventional anti-diarrhoic agents.  
5-HT4 receptor agonists 
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      5-HT4 receptor agonists are known to evoke a potent prokinetic effect 
throughout the gastrointestinal tract. Stimulation of 5-HT4 increases colonic transit 
time and inhibits visceral sensitivity. The most extensively studied 5-HT4 receptor 
agonists include cisapride, tegaserod and prucalopride. Tegaserod is approved by 
the FDA for the treatment of constipation-predominant IBS in women. A study 
showed that tegaserod was superior to placebo at the dosages of 12mg in 
constipation-predominant female IBS patients (Evans et al, 2004). Prucalopride is 
being investigated for a range of conditions including constipation-predominant 
IBS and slow transit constipation with higher efficacy compared to placebo (De 
Giorgio et al, 2004). 
 
      Given the variability of IBS, The most successful treatment will be 
comprehensive, involving multiple strategies (Figure 1-4). Patients should be 
allowed to participate actively in their care, and therapies should focus on 
particular types of gastrointestinal dysfunction (Mertz, 2003). Initial treatment 
should include education, reassurance, stress management, and relaxation 









           Constipation-predominant    Diarrhea-predominant           Pain-predominant 
       
Mild 
 
             Guar gum, fiber, exercise           Trial diet excluding 
              Increased fluid intake                 lactose and caffeine; 
                                                                 Other dietary changes 
 Education, reassurance, stress management, and relaxation techniques 
 
                 
            
                   Antispasmodic agent         Loperamide(Imodium),          Antispamodic 
Moderate      pepermint,                      antispasmodic agenet,            agent, tricyclic 




Tricyclic antidepressant, psychotherapy, sedative with antispasmodic agent Severe 
 
 
                    5-HT4 agonist                  5-HT3 antagonist       Serotonin-3 antagonist  
                     (tegaseod)                           (alosetron)                      if diarrhea noted 
Figuer 1-4. Management of IBS (Adapt from Mertz HR, 2003) 
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1.2 Bloating in IBS 
1.2.1 Overview 
Bloating is the most common and bothersome abdominal complaint in 
patients with IBS, and it impairs quality of life. However, it is an ambiguous term 
that alludes both to the subjective sensation and to the objective abdominal 
distention (Azpitoz& Malagelada, 2005). To some patients, bloating refer to a 
subjective sensation of fullness or pressure inside the abdomen. To some 
individuals, bloating represents abdominal distension, or the sensation of excess 
gas. Others describe bloating as a combination of unpleasant abdominal pressure 
and visible distension. In the past few years various clinical studies have raised the 
significance of abdominal bloating as an important, troublesome, and poorly 
understood clinical problem. It is also highly prevalent. In a US households survey, 
15.9% of the adult population reported experiencing abdominal bloating in the 
month before the interview (Sandler et al, 2000). Studies revealed that abdominal 
bloating is second only to abdominal pain as the most frequently reported 
symptom in IBS (Manning et al, 1978 & Maxton et al, 1989).  
 
Bloating, as with most functional gastrointestinal symptoms, is much more 
frequent in women than in men (Chang et al 2001 & Sandler et al, 2000). The 
severity of bloating may very from very mild to severe and uncomfortable. It is 
important to record the patient’s own impression about the presence and severity 
of objective abdominal distention. Bloating may be localized in the upper 
abdomen or in the lower abdomen, as part of IBS or related syndromes. Certainly, 
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a large overlap exists and many patients describe bloating of the entire abdomen 
(Maxton et al, 1992). Bloating may be related to food intake. Some patients claim 
specific food intolerances in connection with bloating. High-fiber foods and fiber 
supplements are frequently reported to worsen bloating (Levitt et al, 1996). Fatty 
foods and carbonated drinks are also frequently reported as offending. Although 
these are supported by some experiment evidence, the relation may actually be 
based on imaginary assumptions in some patients (Azpiroz & Malagelada, 2005).   
 
In most IBS patients, bloating progressively develops during daily activity and 
tends to diminish or disappear after overnight. Also, patients with bloating 
frequently report a visible increase in abdominal girth. It was demonstrated by 
Maxton et al that the abdominal girth, measures at three anatomical levels, 
increased significantly during the day in female IBS patients compared to normal 
controls (Maxton et al, 1991). While Chang et al found that many IBS patients 
with bloating, approximately 24%, report no visible abdominal distention (Chang 
et al, 2001). Some patients reported stress is to worsen bloating and feel better 
when relaxed (Maxton et al, 1992). In some patients, bloating is associated with 
tiredness and difficulties sleeping, and these symptoms altogether impair quality 
of life. In up to 40% of women, bloating gets worse before and during the 
menstrual period (Heitkemper et al, 2004). Additionally, bloating is frequently 
associated with constipation and diarrhea. Therefore, bloating is a significant 




1.2.2 Pathophysiology of Bloating  
   It is not easy to define pathophysiology what constitutes bloating, since the 
mechanisms of disturbed sensation may be different from those that distend the 
abdomen. Three possible factors will be discussed below: distorted sensation, 
physical intra-abdominal expansion and abdominal wall adaptation to content and 
deformation. These mechanisms may play an independent role or may be 
interrelated. Bloating, like many other abdominal symptoms, is probably a 
heterogeneous condition produced by a combination of pathophysiological 
mechanisms that differ among individual patients (Azpiroz & Malagelada, 2005). 
 
1.2.2.1 Mechanisms of distorted sensation 
   The bloating sensation may arise from a hypersensitive abdominal wall that 
produces a sensation of increased abdominal tension perceived by the patient as 
bloating. The sensation may originate from abdominal viscera, as is probably the 
case in patients with functional disorders, in whom normal stimuli within the gut 
may be perceived as bloating. Indeed, visceral hyperalgesia has been described in 
patients with IBS (Azpiroz, 2002). It originally was reported that IBS patients 
have increased sensitivity in large intestine, while later studies have demonstrated 
that the small intestine is also effected (Accarino et al, 1995). Moreover, Kellow 
et al showed increased awareness of physiological small bowel motor activity in 
IBS patients (Kellow et al, 1991). In patients with functional dyspepsia, which 




   In patients with IBS, abdominal bloating may be related to visceral 
hypersensitivity, but neither the mechanism nor the level of the afferent 
dysfunction has been established. Visceral afferent input is modulated by several 
mechanisms operating between the gut and the brain, and conceivably, an 
alteration of these mechanisms could result in bloating sensation. The tolerance of 
mechanical stimuli in the gut depends on muscular activity and compliance. 
Furthermore, the perception depends on the length of intestine exposed at a 
distending stimulus. Moreover, summation effects are similar whether adjacent or 
distant fields are stimulated. This would explain why a focal collection may be 
unperceived, whereas pooling of intestinal contents, even at distant sites, may 
induce bloating (Azpiroz & Malagelada, 2005). Visceral perception also is 
modulated by the interaction of different stimuli in the gut such as intestinal lipid 
(Accarino, 2001). The autonomic nervous system that regulates GI function also 
modifies visceral sensitivity. Some data indicate that IBS patients have increased 
sympathetic activity, and this mechanism may play a role in bloating (Iovino et al, 
1995).  
 
      In IBS patients, altered sensitivity combines with impaired control of gut 
motility, and both dysfunctions may interact to produce their symptoms (Azpiroz, 
2002). This also applies to bloating. Basically, intraluminal trapping of contents 
causing focal distention in a hypersensitive area would have a synergistic effect in 
inducing the symptoms.  
 
1.2.2.2 Mechanisms of physical abdominal expansion 
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       Endoluminal fluid and endoluminal gas may be the potential elements. In 
acute diarrhea conditions and in some cases of postprandial bloating, increased 
volume of intraluminal liquid content may become an important cause of bloating. 
Accumulation of fecal content also may contribute to bloating, particularly in 
patients with constipation. It has been shown that bloating improves in constipated 
patients after laxative treatment, and conversely, bloating can be induced in 
healthy subjects by loperamide-induced constipation (Marcus et al, 1987). 
Intraluminal gas is still considered the most likely candidate to explain bloating. 
However, it is not a simple issue. Gas production is one of the possibilities. Some 
studies suggest that IBS patients have a reduced absorption capacity of certain 
substrates in the small intestine (Rumessen et al, 1988; Fernandezet al, 1993; 
Symons et al, 1992). However, discrepant results have been gained from various 
studies using breath tests, which provide a noninvasive method of intestinal gas 
production measurement. Hence, the mechanism of gas production alone could 
not explain bloating.  
 
      Propulsion and transit of intraluminal gas determine the times for diffusion 
into the blood and for bacterial consumption. Therefore, the rate of gas transit is a 
critical factor that influences the volume and composition of gas in the different 
regions of the gut (El Oufir et al, 1996). Serra et al have measured intestinal gas 
transit and tolerance using a gas challenge test. It has been shown that most 
healthy subjects propel and evacuate as much gas as infused without discomfort. 
In comparison, the majority of IBS patients develop gas retention, increased 
abdominal girth and a feeling of distension (Serra et al, 2001). Measurements of 
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intestinal gas transit have suggested that IBS patients with bloating have impaired 
intestinal handling of gas loads (Caldarella et al, 2002; Serra et al, 2001). Gas 
transit is tuned by a series of reflexes acting at various sites of the GI tract (Harder 
et al, 2004). It has been suggested that the slowing effect of lipids is up-regulated 
in IBS patients (Serra et al, 2002), whereas the prokinetic effect of the distension 
is impaired markedly (Passos et al, 2002). Furthermore, segmental transit study 
using the scintigraphic technique in bloating patients showed that delayed gas 
clearance in patients is caused by impaired small intestinal propulsion, whereas 
colonic transit is normal (Salvioli et al, 2005). 
 
      The mechanism of gas retention in IBS patients remains speculative. Increased 
resistance to gas flow and impaired intestinal propulsion might be the reasons. In 
healthy subjects, it has been shown that increased resistance to gas flow, modeled 
by self-restraint anal gas evacuation, results in gas retention associated both with 
distension and discomfort. By contrast, impaired propulsion, modeled by 
glucagon-induced motor inhibition, produces abdominal distension, but largely 
painless gas retention (Serra et al, 2001). In summary, abdominal distension 
depends on the volume of gas retained, but abdominal discomfort appears to 
derive from failure to propel gas, possibly because of uncoordinated intestinal 
motility. Moreover, abnormal distribution of gas with focal distension at various 
sites would increase perception by spatial summation phenomena (Serra et al, 
1998).  
 
1.2.2.3. Mechanisms of abdominal muscular activity  
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      The abdominal wall plays a key role in bloating. Bloating as a subjective 
sensation could arise from the abdominal wall it self because of increased tension 
or elongation of the abdominal muscles and other support structures (Azpiroz & 
Malagelada, 2005). Actually, bloating could derive from a wall tension increment 
without a net elongation of girth, that is, even in the absence of true abdominal 
distension. For instance, about 25% of patients in a study complained the 
subjective nature of their bloating and were aware that it is not associated to 
objective disstension (Chang et al, 2001). Some data by tape measures has 
revealed that individual girth increase during the episodes of abdominal distension 
in IBS patients (Maxton et al, 1992; Sulliven, 1994). Conversely, Poynard et al 
also using tape measure reported there were no significant differences of girth 
between those claimed visibly distended and those who did not (Poynard et al, 
1992).  
 
      By ambulatory inductance pletismography, a study has suggested that IBS 
patients develop greater girth increment during the day in relation to bloating, 
particularly in the constipation-predominant group (Lea et al, 2003). Meanwhile, a 
dystonic wall could fail to support adequately intra-abdominal contents and make 
the patients feel bloated. Using a multiple electromyographic record, a research 
group demonstrated that a dystonic response of the abdominal wall to intra-
abdominal volume increments in patients with bloating compared with healthy 
subjects (Azpiroz &Malagelada, 2005). Moreover, Tremolaterra et al found that 
similar volumes of gas retention produce greater objective abdominal distention 
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and subjective symptoms in patients with bloating than in healthy controls 
(Tremolaterra et al, 2004).  
 
      In conclusion, abdominal bloating is a troublesome and poorly understood 
clinical problem. It still remains substantially ignored without known 
pathophysiology and effective treatment. It is not even clear to what extent 
individual patients’ complaints of bloating correlate with objective evidence of 
abdominal distention, and this uncertainly regarding the subjective or objective 
origin of the complains further adds to confusion (Azpiroz &Malagelada, 2005). 
Based on the above view, in this thesis, we are trying to find the role of GIT 
transit using bran scan in IBS patients with bloating (See later chapter).  
 
 
1.3 The role of Serotonin in IBS 
      Serotonin (5-hydroxytryptamine, 5-HT) has gained recognition as a 
physiologic mediator of gastrointestinal function and also a component of 
pathophysiologic responses (Gaginella, 1995). Important contributions were made 
by the discipline of pharmacology through identification of subtypes of 5-HT 
receptors using novel agonists and antagonists. Around 95% of the total quantity 
of Serotonin is located in the gastrointestinal tract, and only 5% in the central 
nervous system. There are at least four subtypes of serotonin receptors: 5-HT1 and 
5-HT2 are located mostly in the central nervous system, while 5-HT3 and 5-HT4 
develop their functions in the gastrointestinal tract (Villanueva et al, 2001).     
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1.3.1 Synthesis, distribution and metabolism of Serotonin 
      5-HT is synthesized and localized predominantly in enterochromaffin (EC) 
cells of the gut but also in the enteric nervous system, where it accounts for 90% 
(up to 10 mg in man) of total body 5-HT. It is a major neurotransmitter in the 
gastrointestinal tract (Davidson et al, 1986). Serotonin is synthesized from 
tryptophan, which is first hydroxylated by tryptophan hydroxylase to form 5-
hydroxytryptophan.5-hydroxytryptophan is then decarboxylated by aromatic 
amino acid decarboxylase to give 5-HT (Figure 1-5). The newly synthesized 5-HT 
is stored in storage vesicles and released into synaptic cleft upon nerve impulse. In 
the central and peripheral nervous systems, the 5-HT released is inactivated 
primarily by re-uptake into the serotonergic neurons that secrete it. This re-uptake 
is mediated by a highly selective 5-HT transporter (Croewll, 2004). 
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      Figure 2-1 Outline of the biosynthetic and metabolic pathway of 5-HT (Adapt 
from Reiter, 1998, www.appi.org) 
 
      In the central nervous system, 5-HT is synthesized within the nerve terminal. 
The 5-HT produced in the EC cell of the gut is distributed to the rest of the body, 
except CNS, since 5-HT does not cross the blood-brain barrier. 5-HT neurons are 
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restricted to clusters of cells around the midline of pons and upper brain stem. 
While in the gut, the EC cells containing 5-HT are localized primarily in the 
Lieberekuhn’s crypts and at the base of villi of the small intestine. The amount of 
5-HT in the tissue is a dynamic function of synthesis, release, and metabolism, 
each of which can be influenced by physiology and drugs (Gaginella 1995). 5-HT 
can be released physiologically during neurotransmission, in response to pressure 
exerted in the intestinal mucosa or by other mediators. Release of 5-HT is 
regulated by humeral as well as neural factors that activate receptors on myenteric 
neurons and EC cells. In the gastrointestinal tract, 5-HT1, 5-HT2, 5-HT3 and 5-
HT4 subtypes have been most studies.  
 
1.3.2 Serotonin in GIT 
       5-HT clearly plays a significant role and exerts it wide range of effects 
through actions on numerous receptor subtypes in GIT. 5-HT receptors are 
involved in the mediation of reflexes controlling gastrointestinal motility and 
secretion, and appear to be important in the perception of GI sensation (Crowell, 
2004). Local mucosal stimulation induces the release of 5-HT from EC cell within 
mucosal crypts and initiates the peristaltic reflex. 5-HT stimulates the intrinsic, 
primary, afferent neurons (IPANs) that synapse in the myenteric plexus with 
ascending and descending interneurons, thus inducing excitation and inhibition 
locally (Pan& Gershon, 2000). Also, Grider et al concluded that 5-HT was 




      Coordinated neuromuscular activity associated with the peristaltic reflex 
facilitates the oro-aboral transit of materials through the GIT. Coordinated 
intestinal contractions and transit appear to be modulated by 5-HT acting on 
specific receptor subtypes. Activation of 5-HT3 or 5-HT4 receptors enhances 
gastrointestinal transit (Crowell, 2004). Additionally, intrinsic afferents, utilizing 
5-HT3 receptors, may be involved in a reflex circuit within the gut that increases 
motility and intestinal secretions (Bardhan et al, 2000). Antagonism of the 5-HT3 
receptors with ondansetron or alosetron delays colonic transit in healthy controls 
and in D-IBS patients (Gore et al, 1990). Preclinical studies suggest that 5-HT4 
receptor antagonists should also induce significant slowing of intestinal transit and 
provide potential therapeutic benefits to D-IBS. 5-HT4 receptor agonists, such as 
tegaserod and prucalopride, accelerate gastrointestinal transit. Prucalopride 
appears to have little effect on gastric or small bowel transit (Bouras et al, 1999). 
However, tegaserod has been shown to accelerate both gastric emptying and small 
bowel transit (Degen et al, 2001). These data suggest that antagonizing the 5-HT3 
receptor slows intestinal transit and that agonizing the 5-HT4 receptor accelerates 
gastrointestinal transit. These observations have led to increased efforts to develop 
and evaluate the treatment of IBS.  
 
1.3.3 Effects of 5-HT4 agonist on IBS 
      Tegaserod is a selective partial agonist at the serotonin type-4 receptors (5-
HT4 receptors), which mediate physiological functions in the gastrointestinal tract. 
The chemical name of tegaserod is 3-(5-methocxy-1H-indol-3ylmethylene)-N-
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pentyl- carbazimidamide. It is an aminoguanidine-indole derivative structurally 
similar to serotonin. 5-HT4 receptors are located on intrinsic primary afferent 
neurons, cholinergic interneurones that activate excitatory and inhibitory neurons 
involved in the peristaltic reflex, and conceivably extrinsic visceral afferents 
(Camilleri, 2001). As a partial agonist at the 5-HT4 receptor, tegaserod less likely 
to induce receptor desensitization, compared to full agonists; it is also likely to 
produce a normalizing effect, augmenting the insufficient endogenous stimulation, 
and preventing the exaggerated affects associated with full agonists. Thus, 
tegaserod should provide a balanced modulation of the 5-HT4 receptors (Kenakin, 
1997). 
 
      In vivo studies show that tegaserod enhances motility at all levels of the 
gastrointestinal tract. It stimulated gastric emptying in rats and dogs under normal 
or perturbed conditions. In dogs, Nguyen et al found that intravenous tegaserod 
activated small intestinal rhythmic contractions and induced prolonged colonic 
contractions (Nguyen et al, 1997). Also, another study demonstrated that 
tegaserod stimulated small bowel and colonic motility in dogs in a dose-dependent 
manner (Appel et al, 1996). Furthermore, studies tested the activity of tegaserod 
on noxious colonic and rectal hypersenstitivity in animal models. Tegaseod 
inhibited the abdominal contractions in response to colorectal distention of the rat 
(Schikowski et al, 1999).  
 
      Recent work suggested that tegaserod, directly inhibited mechanosensitive 
afferents in response to rectal balloon distention in an animal model (Schikowski 
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et al, 2002). The mechanism that modulates pain transmission is not clearly 
known. Tegaserod, a highly selective partial agonist, might be expected to 
compete with endogenous 5-HT to functionally antagonize these 5-HT4 receptors, 
thus reducing afferent transmission (Grundy, 2002). Clearly, additional work is 
needed to clarify the modulation of pain pathways. 
 
      In humans, Degen et al revealed that intravenous (0.6mg) and oral (6mg) 
tegaserod accelerate gastric emptying, small bowel and colonic transit (Degen et 
al, 2000). Additionally, Prather et al. evaluated the effect of 2mg bid of tegaserod 
for 1 week on whole gut transit using a scintigraphic method; colonic filling, a 
surrogate of orocecal transit time, was significantly accelerated by tegaserod 
relative to placebo ( Prather et al, 2000). In several large, well-designed, 
randomized, placebo-controlled 12-week clinical trials, tegaserod was shown to 
improve global IBS symptoms and specific abdominal symptoms (such as pain, 
bloating and constipation). (Cash et al, 2004).As consequence of these trials, 
tegaserod was approved by the FDA for use in women who have C-IBS. The most 
common adverse events those are associated with tegaserod are diarrhea and 
headache. 
 
        In summary, tegaserod is a potent 5-HT4 receptor partial agonist which has 
shown efficacy in the treatment of abdominal pain and constipation in female 
patients with irritable bowel syndrome. Tegaserod appear to have an effect on 
visceral afferent function, reducing pain and discomfort associated with noxious 
distensions of the colorectum in animals and increasing motility as well as 
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accelerating transit in the small bowel and colon. Further studies are necessary to 
more fully demonstrate the efficacy of the medication and its mode of action.  
 
1.4 Hypothesis and Aims 
   As discussed above, numerous studies suggested that there is a correlation 
between patient’s predominant symptom and an underlying pathogenic 
mechanism. Postprandial fullness appears to be associated with delayed gastric 
emptying (Stanghellini et al, 1999). Recent studies in IBS reported that bloating is 
associated with impaired gas transit in the proximal small bowel (Serra et al, 
2001). Moreover, Trotman investigated the ileocaecal region is a possible 
mechanism for bloating in IBS (Trotman et al, 1986). We thus wish to explore the 
pathophysiology of bloating in IBS patients and hypothesize that these IBS 
patients have impaired intestinal transit. In addition, we propose to test the effect 
of treatment with an intestinal prokinetic agent, tegaserod, on bloating and 
intestinal transit.  
 
The aims of this study are to determine:  
1) To investigate the baseline gastrointestinal & bowel symptoms and 
psychological profiles of healthy controls, IBS patients. 
2) To assess the effects of tegaserod on gastrointestinal & bowel symptoms and 
psychological status in IBS patients. 
3) IBS patients with bloating have impaired transit in the small bowel intestine 
time. 
4) The bran scan can be used to reproduce bloating in patients with IBS, and to 
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test transit time in GIT and the therapeutic effect of pharmacological agents on 
relieving bloating.  
5) Tegaserod can be used to accelerate impaired transit in the small intestine and 
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      Irritable bowel syndrome is a common, chronic gastrointestinal disorder that 
occurs as the absence of any organic disease. There is a wide variation in the 
predominant symptom: pain/bloating/discomfort, constipation, diarrhea, or 
alternating between constipation and diarrhea. Bloating is one of the most 
bothersome complaints and less understood symptoms in IBS. It usually occurs in 
combination with other symptoms.  
 
      Bloating is a common complaint in the general population. In a survey of US 
households, 16% reported experiencing abdominal bloating in the month of the 
interview, and 65% of the respondents complained of moderate to severe bloating 
(Sandler et al, 2000). Bloating is also usually considered to be part of the spectrum 
of irritable bowel syndrome or nonulcer dyspepsia when an organic problem could 
not be found. Chang et al. demonstrated that bloating-type symptoms made up the 
majority of non-painful symptoms of IBS and were recognized as the most 
bothersome symptom by a majority of patients (Chang et al, 2001). A study by 
Maxton et al also revealed that abdominal bloating is second only to abdominal 
pain as the most frequently reported symptom in functional bowel disorders 
(Maxton et al, 1989). Patients with bloating often report a visible increase in 
abdominal girth. Characteristically, it worsens as the day progresses and tends to 
improve or disappear overnight (Zar et al, 2002). Bloating can be present in upper 
or lower abdomen, associated with other IBS relevant symptoms such as 
constipation or diarrhea.  
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More women report bloating problem than men. Meanwhile, bloating gets 
worse before and during the menstrual period in about 40% female IBS patients 
(Heitkemper et al, 2004). Specific food can be viewed as the factor of bloating in 
some IBS patients. It was reported that high fiber and fiber supplements worsen 
bloating (Levitt et al, 1996). It was found that some patients reported stress 
worsen bloating and feel better when relaxed (Maxton et al, 1992). It also was 
revealed that psychological stress was associated with the onset or exacerbation of 
symptoms in approximately 50-80% of IBS patients (Hislop, 1971). Lastly, a 
more recent study showed that high anxiety and depression scores predicted the 
development of post-infectious IBS (Gwee et al, 1999). 
 
      However, little has been reported about IBS patients with bloating in Asia. 
Thus we aim to find out the status and characteristics of bloating in IBS subjects, 
who are recruited from Singapore using a series of IBS related symptom and 
psychological questionnaires. Singapore population is comprised of an ethnic mix 
of Asians such as Chinese, Malay and Indian. However, this study was only a 
small-scale survey in IBS patients. It is not an epidemiological study of all IBS 
patients in Asia due to limited research resource.  
 
 
2.2 Subjects and Methods 
    
2.2.1   Subjects 
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      There were two groups of subjects recruited in this study: bloating 
predominant IBS patients and healthy volunteers. Patients predominantly 
reporting abdominal bloating were recruited from University Digestion Centre, 
NUH. They have satisfied inclusion criteria of having the diagnosis of IBS made 
by experienced gastroenterologists (GKA&HKY) based on the Rome II criteria 
(Thompson et al, 1999). In addition, their bloating score had to be higher than 1 
on a 5-point scale. All patients were symptomatic at the time of study. These 
subjects were asked not to take any medications known to alter gastrointestinal 
and bowel function within a month before and during the study, and their history 
of medications was recorded.  Healthy subjects were recruited by public 
advertisement and completed a pre-entry questionnaire to establish the absence of 
gastrointestinal symptoms. Written consent was obtained from each subject. The 
study protocol was previously approved by the Institutional Review Board of 
National University Hospital. 
 
Inclusion criteria 
For patients with bloating predominant IBS those meet Rome II criteria: 
1. Presence of bloating associated with non-Diarrhea-IBS for at least 3 
months in the absence of organic, systemic or metabolic disease. 
2. Bloating score should be ≥ 2 on a 5-point scale i.e. at least have moderate 
bloating as most bothersome complaint. 
3. Presence of normal baseline Haematology and Chemistry screens. Values 
should be within 1.5× upper normal limit.  
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For healthy volunteers: 
1. Without regular stomach or bowel symptoms 
2. Without a past history of peptic ulcer, or major abdominal surgery 
3. Without any major illnesses or require regular medications. 
 
Exclusion criteria 
     1. History of peptic ulcer, major abdominal surgery, or psychiatric disease.  
     2. Use of NSAIDs, steroids, H2 receptor antagonists or proton-pump inhibitors 
         in the four weeks preceding the study. 
     3. Presence of oesophagitis, gastric atrophy, erosive gastroduodenal lesions or 
         peptic ulcers on endoscope. 
     4. Allergy to Zelmac. 
     5. Female subjects who are pregnant. 
 
2.2.2 Methods 
Gastrointestinal Symptoms Questionnaire (Appendix A) 
It is a detailed symptom assessment with gastrointestinal questionnaire 
including Rome II criteria for the diagnosis of IBS, detailed descriptions of 
bloating complaint such as 1)severity, 2)location (a diagram showing the abdomen 
divided into 9 parts: epigastrium, umbilical region, hypogastrium, bilateral 
hypochondria, bilateral lumbar regions, and bilateral iliac fossae), 3)whether 
relieved with belching or passage of stool or flatus, 4)any known precipitating 
factors and 5)whether there is visible distension. Upper gut symptoms assessment 
is also included such as early satiety, nausea. Bowel habit assessment consists of 
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frequency and pattern of bowel movement as well as a series of related symptoms 
such as straining, feeling of incomplete defecation, etc.  Severity was prescribed 
as None, Mild, Moderate, or Severe. “Mild” represents “awareness of symptoms, 
no interference with daily activity and it can be ignored”. “Moderate” means 
“some interference with daily activities and it can not be ignored; but can continue 
with work/daily activities”. “Severe” represents that “unable to conduct a range of 
daily activities, affects concentration on work and daily activities”.  
 
Hospital Anxiety and Depression scale (HAD) (Appendix B) 
      The HAD (Hospital Anxiety and Depression Scale, Zigmond and Snaith, 1983) 
consists of a total of 14 items and 2 subscales (anxiety and depression) with 7 
items each. Answers to each item are given scores of 0-3. The scores for each 
subscale were added to give anxiety scores and depression scores. Thus the 
maximum obtainable score for either anxiety or depression was 21. Particularly, 
score 0-7 means a normal case, score 8-10 represents a borderline abnormal case, 
and score 11-21 is described as abnormal.  
 
Symptoms Score (based on Likert Scale) (Appendix C) 
      Bloating predominant IBS patients and healthy volunteers in our study were 
asked to assess their symptoms (bloating, pain, fullness, belching, nausea, flatus) 
with scores ranging from 0-4 (0 for none, 1 for mild, 2 for moderate, 3 for 
moderate severe, 4 for severe).  
 
2.2.3 Statistical analysis 
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All statistical analyses were performed using standard SPSS package (version 
13.0 for windows). Continuous variables were expressed as Mean ± S.E.M, and 
categorical variables were expressed as frequencies and percentages. To compare 
the differences between IBS and healthy control groups, chi-squared test was used 
for categorical variables and independent samples t-test for continuous variables. 
Non-parametric data were analyzed using the Mann-Whitney U test. Two tailed p 





2.3.1 Demographic Characteristics of IBS patients and Healthy subjects 
      Thirty-seven IBS patients with bloating (age: Mean ± SEM, 39.5±2.2; age 
range 20-59 years) and twelve healthy volunteers (age: 31.5±3.0; age range, 21-
50years) who met the inclusion and exclusion criteria were recruited. There were 
22(59.5%) females and 15 (40.5%) males in IBS with bloating group. Among IBS 
group, there were 25 (67.6%) Chinese, 8 (21.6%) Indian and 4(10.8%) Malay. 
There were 6 (50%) Chinese, 5 (41.7%) Indian and 1 (8.3%) Malay subjects in 
normal controls. In bloating IBS patients, the mean duration of symptoms was 2.9 







 Table 2-1 Demographic Data of Bloating IBS patients and Normal Controls 
Normal Controls      Bloating IBS        P value 
(n=12)                            (n=37) 
Sex [n (%)]                                                                                                      0.5 
    Male                                              6 (50)                        15 (40.5) 
    Female                                           6 (50)                        22 (59.5) 
Race [n (%)]                                                                                                    0.4 
    Chinese                                         6 (50)                         25(67.6) 
     Indian                                           5 (41.7)                       8 (21.6) 
     Malay                                           1 (8.3)                         4(10.8) 
Age (Y)                                                                                                           0.03 
     Mean (SEM)                                31.5 (3.0)                  39.5 (2.2) 
     Median                                         29.0                           40 
Weight(Kg)                                                                                                     0.4 
      Mean (SEM)                                61.4(2.7)                   57.6 (1.9)  
Duration of Bloating  
symptom (Y)                                                                                                   --- 







2.3.2 Characteristics of the Sensation of Bloating 
      All 37 bloating IBS patients had at least moderate bloating symptom 
(moderate: 83.8%; severe: 16.2%), while none of the healthy subjects complained 
of bloating (Table 2-2). The most common sites of abdominal bloating were in the 
umbilical and epigastric regions (Fig 2-1). Bloating was worse in the afternoon in 
48.6% patients and in the evening in 24.3%. There were 10.8% of them 
experiencing worse bloating in the morning (Fig 2-2). Bloating was relieved in the 
great majority of patients by the passage of gas and stool (75.7% and 75.7%, 
respectively). Other factors which improved the sensation of bloating, such as 
belching (45.9%) and vomiting (8.1%) were less frequently reported (Fig 2-3). In 
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these bloating IBS patients, 43.2% of them reported their bowel movements 
became less frequent and 70.3% had harder stools when they had the bloating 
sensation (Table 2-3). Eleven of these bloating patients with IBS (29.7%) thought 
certain food or stress was the precipitating factor for the bloating. Meanwhile, 





Table 2-2 Severity of Bloating in Bloating-IBS patients  
Bloating IBS          
 (n=37)                 
Severity of Bloating (n (%)) 
                   None                                0 (0%) 
                                       
                   Mild                                 0 (0%)    
                                        
                   Moderate                         31 (83.8%)       
 
                   Severe                               6 (16.2%)        

















Fig 2-1 Diagram shows numbers of patients who reported bloating referred to 























Fig 2-2   Worse sensation of bloating in different time  
 
 52
Table 2-3 Symptom characteristics associated with bloating in Bloating IBS 
patients 
Bloating IBS patients 
         N (%) 
Bloating symptom relieved by 
                       Belching                                     17 (45.9%)  
                  
                       Vomiting                                     3 (8.1%) 
                       Pass motion                                28 (75.7%) 
                       Pass flatus                                   28(75.7%) 
Onset of bloating associated with  
change in bowel movement 
                   More frequent                                  3 (8.1%) 
                    Less frequent                                  16 (43.2%) 
                    Loose                                               2 (5.4%) 


























Fig 2-3   Different relief ways of bloating symptom 
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2.3.3 Bowel Habits  
      All subjects were also asked to describe their bowel pattern in the last one 
month. As our study requirement, none of them had diarrhea problem. All of the 
normal controls reported their bowel pattern were normal without any bowel 
symptoms (frequency, consistency, incomplete defecation, straining etc). 43.2% 
of the patients self-described their bowel pattern as normal, 37.8% had 
constipation and 18.9% as alternating (Fig 2-4). 27.0% of them reported their 
bowel movement was less than 3 times a week. The majority (92%) had no 
experience of bowel movement more than 3 times a day. 29 patients (78.4%) 
passed hard stools (32.4% mild, 35.1% moderate and 10.8% severe). Most of 
them (86.5%) had experience of incomplete defecation (48.6% mild, 27.0% 
moderate and 10.8% severe). The prevalence of feeling of “strain to pass motion” 
and “urgency to pass motion” among these bloating IBS patients was 59.5% and 



















Fig 2-4    Bowel Pattern in bloating IBS patients  
 
 
Table 2-4    Bowel symptoms of bloating IBS patients 
                                                                          Bloating IBS patients   
N (%) 
Bowel movements less than 3 times 
     a week                                                                    10 (27.0%) 
Bowel movements more than 3 times 
     a day                                                                       3 (8.1%) 
Strain to pass motion                                                  22(59.5%) 
Urgent to pass motion                                                18 (48.6%) 
Presence of mucus in stools                                        4 (10.8%) 
Hard stool form                                                           29 (78.4%) 
                 Mild                                                           12 (32.4%) 
                 Moderate                                                    13(35.1%) 
                 Severe                                                         4 (10.8%) 
Feeling of incomplete defecation                                32 (86.5%) 
                Mild                                                             18 (48.6%) 
                Moderate                                                     10 (27.0%) 
                Severe                                                          4 (10.8%) 
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 2.3.4 Symptom Score and HAD Score 
      The symptoms score by Likert 5 point scale was used to assess the subjects’ 
relevant sensations. The mean total symptom score of bloating IBS patients 
(10.4±0.8) was significantly higher than normal controls (0.5±0.2, p=0.00) (Fig 2-
5). The patients with visible distension did not have greater symptom scores 
(P=1.0) than those without visible distension. 
 
      The data got from HAD showed that the mean total anxiety score of these 
bloating IBS patients was 8.3, which was higher than the recommended normal 7. 
While, the mean total depression score of them was 4.1, which was within the 
normal range (Table 2-5). Both scores were significantly higher than those in 
normal controls. No significant correlation was showed between symptoms score 























Fig 2-5  Total Symptom Scores of Bloating IBS patients and Normal controls.  





Table 2-5 HAD Scores of Bloating IBS patients and Normal controls 
HAD Scores                Bloating IBS patients          Normal Controls           P value 
Anxiety                              8.3±0.8                                2.2±0.3                       0.00 








2.3.5 Survey of IBS education 
      From this survey form, 37.8% of the 37 bloating IBS patients had been 
diagnosed as IBS. There was still 18 (48.6%) of them did not heard or know about 
IBS before and 20 (54.1%) patients thought the bloating symptom is related to the 





Table 2-6 Survey on IBS education 
                                                                                 YES                         NO 
                                                                                  n (%)                      n (%) 
Have you Diagnosed as IBS before?                  14 (37.8%)               23 (62.2%) 
Have you heard or known about IBS before?    19 (51.4%)               18 (48.6%) 












         In the current study, we have shown the nature of bloating complaints in IBS 
in Asian population. Abdominal bloating is frequently reported by IBS patients. 
All the IBS patients in the present study had at least moderate bloating problem, 
thus a typical patient pool worth investigating. These patients were recruited from 
outpatient clinic with the duration of bloating for at least a year or more, which 
means that bloating was bothersome problem with recurrence for them and 
objectively affected their daily activities or quality of life. The majority of our 
patients in this study reported that bloating was relieved by passing stool (75.7%) 
or flatus (75.7%). This finding was similar to the results of a previous study by 
Chang et al. (Chang et al, 2001), which assessed symptoms related to bloating 
with IBS. Onset of bloating more than half of them (70.3%) reported the change 
of stool consistency—becoming harder. 
 
         In our study, we found that IBS patients in Asian population presented more 
common with upper abdominal bloating and the most common sites were 
umbilical and epigastrium regions. By contrast, IBS patients in western countries 
have more frequently complaint with lower abdominal bloating (Talley et al, 
2001). Similarly, this difference in pain site was also reported in IBS patients. In 
more recent Asia studies, more than half of IBS patients reported upper abdominal 
pain (Gwee et al, 2004 & Masud et al, 2001), whereas in the western society most 
of the patients presented with lower abdominal pain (Talley et al, 2001).  This 
may suggest the nature of bloating appears differently in different racial 
populations.      
 59
       A large proportion of patients in the present study complained that their 
bloating symptoms worsened during the day, especially in the afternoon and 
evening (totally 72.9%). Similarly, in Sullivan’s study, 73% of patients with 
bloating reported bloating progressively worsened during the day and was worse 
in the early evening hours, but was gone the following morning when they awoke 
from sleep (Sullivan, 1994).  In an earlier study, 74% of IBS patients reported 
abdominal pain and distension coinciding with the arrival of meal residues in the 
colon (Cann et al, 1983). Additionally, a more recent study found that IBS patients 
had enhanced perception of infused gas loads and impaired intestinal transit, 
resulting in symptoms of abdominal bloating and distension (Serra et al, 2001). 
These findings may suggest that the progressive worsening of bloating during the 
day and its exacerbation by meals (Chang et al, 2001). It is possible that bloating 
in IBS patients could arise from enhanced production of intestinal gas, particularly 
during the fermentation of meal residues in the intestine (Rao, 1997). Furthermore, 
the impaired intestinal gas /solid transit in IBS patients may result in the 
worsening of bloating in the afternoon (after lunch) and evening (after dinner). In 
addition, the enhanced perception of gas could be one of the possible reasons 
(Chang et al, 2001). Hence, these factors, either alone or in variable combinations, 
may explain the worsening of bloating in the afternoon and evening.  
 
 Among those 35% of patients who described their bloating were visible 
abdominal distension, were mostly female patients. It is assumed that the 
complaint of abdominal distension is often voiced by women. The reason is that 
they pay more attention to that than men and feel their figure is becoming 
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distorted as the day goes on and their clothes do no fit well (Azpiroz & 
Malagelada, 2005). It appears that we got inconsistent data compared to Chang’s 
study conducted in US, which showed 75% of the bloating IBS patients reporting 
visible abdominal distention (Chang et al, 2001). Nevertheless, percentage of 
female patients in our study (59.5%) was much lower than that in Chang’s study 
(70%). In addition, their study was of a larger sample size (542 patients). These 
possible reasons may result in the different prevalence of visible abdominal 
distention.  
 
      Our data showed that almost half of these patients with IBS criteria self-
described that their bowel patterns were normal in the past one month.  However, 
when they were asked specific questions about defecatory symptoms, they 
realized the disturbances: more than half of them (78.4%) passed hard stools 
forms, 27.0% experienced bowel movement less than 3 times a week, and the 
majority of them (86.5%) had feeling of incomplete defecation. This perhaps 
implicates that defecatory and stool problems were less bothering than abdominal 
bloating. Also, it could explain why there was still 45.9% of them did not think 
bloating is correlated to the bowel in the IBS education survey. The importance of 
this finding suggests that if a patient with abdominal pain/bloating is simply asked 
whether there is a problem with the bowels, the diagnosis may be missed in a 
substantial majority (Gwee et al, 2004). If the doctors fail to recognize IBS, 
patients with abdominal pain/bloating may be referred for irrelevant investigations. 
Therefore, it is important for doctor to realize the prevalence of IBS and be 
familiar with the symptom patterns of IBS.  
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 Furthermore, from the IBS education survey we noticed that among these 
IBS patients, more than half of them were not diagnosed as IBS before. Still 49% 
of these patients have not heard or known about IBS. Hence, it is crucial for 
general practitioners to be more familiar with IBS and bring the information to 
patients. On the other hand, it is also important for health authorities to provide 
more IBS health education and more health-care costs about IBS in Asian 
population.  
 
In addition, both anxiety and depression scores for IBS patients with 
bloating were significant higher than normal controls. Substantial literatures have 
suggested that there is a high prevalence of mood disorders in IBS patients. IBS 
could be associated with changed in mood, especially depression and anxiety. 
Conversely, depression and anxiety might aggravate the IBS symptoms such as 
pain/ bloating, bowel movement and affect the quality of life (Barbara et al, 2004). 
However, the anxiety symptoms of the present IBS patients were not severe 
enough to be classified as anxiety disorder because their score (8.3) was still less 
than 10 (8-10 is borderline abnormal). Moreover, the depression scores of them 
were still within the normal range.  These findings were relatively milder than 
those observed in western populations, which were reported to have higher scores 
(Whitehead et al, 1980; Svedlund et al, 1985). One possible explanation for this 
difference was we used a different race and relative younger population. In 
addition, this difference may be due to our relatively small sample size. On the 
other hand, the HAD scale is probably not sensitive enough to detect the 
psychological status for Asian population.  
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In conclusion, the present study showed the characteristics of symptoms in 
bloating IBS patients in Asian population. Despite some similar profile to western 
population, we still found more common complaint with upper abdominal 
bloating, associated with moderate bowel disturbance presented in our Asian IBS 
patients. In addition, they had significant higher anxiety and depression scores 

































Chapter 3   
 
 
Impaired Intestine Transit in  
Non-Diarrhea Irritable Bowel 






















3.1 Introduction  
      Bloating is an important but poorly understood symptom in irritable bowel 
syndrome (IBS). Although the pathophysiology of bloating still remains unclear, 
study evidences from the past decades have suggested some possible mechanisms 
such as abnormal sensation, gas trapping, food intolerance, altered intestine transit 
etc.  
 
      It has been shown that abdominal bloating is second only to abdominal pain as 
the most frequently reported symptom in IBS (Manning et al, 1978; Maxton et al, 
1989). Other studies showed that the complaints of bloating by IBS patients are 
accompanied by increased abdominal girth (Maxton et al, 1991& 1992). Moreover, 
in a study of 724 IBS patients with bloating, Chang et al demonstrated that 
bloating and visible abdominal distension may arise from two distinct but 
interrelated physiological processes (Chang et al, 2001). In the 1970s, Levitt et al 
measured the volume of intestinal gas using a washout technique and determined 
that IBS patients have normal gas volumes in gut (Levitt et al, 1971).  
 
      In fact, some early studies supported the idea that bloating may be associated 
with impaired intestinal transit. Trotman and Price fed bran labeled with TC99m 
isotope and scanned the ileocaecal area using a gamma camera (Trotman & Price, 
1986). They found that none of ten women with IBS and bloating were able to 
discharge at least half the bran into the caecum, whereas all eight healthy controls 
were able to do so. Hence they suggested impaired ileocaecal transit may be the 
possible mechanism for bloating in IBS. Furthermore, a study using a similar 
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radioscintigraphic method observed that IBS patients complaining predominantly 
of pain and bloating had significantly longer intestinal transit time than normal 
controls (Cann et al, 1983). Additionally, in more than half of these IBS patients, 
it is found that the onset of pain was associated with the arrival of the test meal in 
the caecum. They indicated that irritable bowel syndrome should be considered a 
disease of the small intestine as well as the colon.  
 
      Recently, a series of studies from a research group in Spain suggested that 
impaired transit and tolerance of intestinal gas may be responsible for the bloating 
in IBS. When gas was infused into the jejunum of IBS patients, there was a high 
correlation between gas retention and the development of symptoms and 
measurable abdominal distension compared with normal controls (Serra et al, 
2001). Using this gas challenge test, it is found motor dysfunction in patients with 
IBS, which results in gas retention within the gut and the appearance of symptoms 
(Caldarella et al, 2002). By the same test, this research group further showed 
lipids exert an inhibitory control on intestinal gas transit in IBS (Serra et al, 2002). 
More recently, they concluded that total gut transit of gas was delayed in bloating 
IBS patients by a radioscintigraphic technique, while the colonic transit was 
normal (Salvioli et al, 2005).  
 
      On the other hand, it was suggested in 1970’s that “fiber deficiency” could be 
the cause of IBS, and this led to a trend recommending the use of products such as 
bran to help this condition. However, a number of trials of fiber subsequently 
reported generally disappointing results, particularly with bran (Lewis&Whorwell, 
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1998). In a study reported in 1994, it is demonstrated that bran may actually 
exacerbate the symptoms of patients with IBS (Francis et al, 1994). Also, Can et 
al reported that pain and urgency were significantly more frequent in patients 
receiving bran (Cann et al, 1984).  Furthermore, it is reported by Hebden et al. that 
bran can affect GI transit in bloated irritable bowel syndrome. They suggested that 
bran-induced bloating may originate in the colon rather than the small bowel by a 
scintigraphic imaging method. (Hebden et al, 2002).   
 
      In the Asian population, IBS patients appear to be more bothered by upper 
abdominal symptoms, and in particular bloating. In an epidemiology study of 
3,000 households in Singapore, it was found that 62.1% of IBS subjects 
complained of bloating (Gwee et al, 2004). In the present study, we wish to find 
that bran can be used to reproduce bloating in IBS patients and whether there is a 
difference in response to bran between bloating IBS patients and normal controls. 
Moreover, we wish to further explore the pathophysiology of bloating by using 
the Tc99m isotope method, which particularly tests the hypothesis that impaired 




3.2  Subjects and Methods  
3.2.1 Subjects 
      Thirty non-diarrhea IBS patients predominantly reporting abdominal bloating 
were recruited from University Digestion Centre, NUH. They have satisfied 
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inclusion criteria of having the diagnosis of IBS made by experienced 
gastroenterologists (GKA&HKY) based on the Rome II criteria (Thompson et al, 
1999). In addition, their bloating score have to be higher than 1 on a 5-point scale 
(at least have moderate bloating). All patients were symptomatic at the time of 
study. These subjects were asked not to take any medications known to alter 
gastrointestinal and bowel function within a month before and during the study, 
and their history of medications was recorded. Twelve healthy subjects (same as 
described in Chapter 2) were recruited by public advertising and completed a pre-
entry questionnaire to establish the absence of gastrointestinal symptoms. Written 
consent was obtained from each subject. The study protocol was previously 
approved by the Institutional Review Board of National University Hospital. (See 
details of Inclusion and exclusion criteria in Chapter 2.2.1) 
 
3.2.2 Procedure  
      All subjects were required to do bran scan. Participants were instructed to 
follow a diet excluding legumes, vegetables, garlic, onion, nuts, cereals, whole 
meal bread, and fizzy drinks during the two days before the study. The night 
before the bran scan, they had a light dinner that could consist of meat, fish, eggs, 
rice, and/or white bread but were instructed to avoid dairy products, salad, fruit 
and alcoholic beverages. On the day of the study, a bran scan was done for a 
maximum of six hours which is a radioisotope scan by gamma camera after 
subjects had taken bran and isotope (TC99m)-egg sandwich.  
Bran Scan 
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       Radioisotope scan by gamma camera is to measure gastric and intestinal 
transit and to correlate with symptoms in bloating IBS patients and healthy 
controls. Subjects were studied after overnight fast. The meal is made up of 30g 
bran (Unprocessed Bran, Sanitarium)-soymilk (100mL) slurry followed 20minutes 
later by radiolabelled scrambled egg (20MBq of Tc99m-Sn colloid). The 
radiocolloid was well mixed with the raw egg prior to gentle cooking in a fry pan. 
The scrambled egg (two 60g eggs) was mashed to particles roughly of about 4-
5mm cubes. One frond of vegetable (chopped & lightly fried) and two slices of 
tomato (lightly fried) were added to the egg and placed between two slices of 
white bread. This will be an easily eaten meal, requiring no chewing and little 
swallowing effort on the part of the patients and with a consistent time for 
consumption. The radiation quality control was conducted by Shuter B (Radiation 
Safe Officer, NUH). 
 
      Subjects are asked to eat the radiolabelled meal. We note time at start and end 
of eating. They have to consume the entire meal. A small amount of water may be 
given to alleviate esophageal discomfort if it occurs. The complete data collection 
may take 4-6 hours. Subjects stand comfortably in front of the gamma camera 
(XR/T, GE; StarCam 4000, GE). We positioned the camera so the stomach 
appears high, allowing the bowel transit to be imaged below. We collected the 
anterior view (128x128; 30s) and then (after patient rotates around) the posterior 
view (also 30s). Subjects were given the remainder of 120mls of water to drink. 
We repeated anterior and posterior imaging at 3-minute intervals for the first 10 
minutes (patient may continue to stand in front of the camera or sit as is necessary 
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or comfortable). We continued anterior and posterior imaging at 5-min intervals 
for next 15 minutes; 8-min intervals for following 30 minutes; 12-min intervals 
for next 60 minutes. We imaged the small bowel transit, repeat anterior and 
posterior imaging at 18-min intervals for up to 6 hours or until the ascending 
colon become visible. 
               
      During the bran scan, at 15 minutes interval, the subjects were asked to assess 
intensity of bloating symptoms (Score range 0-4, 0 for none, 1 for mild, 2 for 
moderate, 3 for moderate severe, 4 for severe). We also measured the girth of 
subjects every 15 min. The subjects stood up when the girth measurements were 
taken. Measurements were taken by a metric tape while the subjects were 
breathing in a relaxed manner as the average of inspiratory and expiratory 
determinations over three consecutive respiratory excursions. A standard meal 
(Chicken Pie) was given at 3 hours after starting scan. Other meals were not 
allowed. 
 
3.2.3 Scintigraphic Analysis  
      For analysis, we used the software using MATLAB written by Dr Shuter 
Borys based on that used at RNSH Sydney for many years, but further developed 
at National University Hospital, Singapore) to calculate stomach emptying lag 
time, half emptying time, terminal ileum and caecum arrival time. Scintigraphic 
images for each subject were reviewed, and outline of the stomach, terminal ileum 
and caecum were constructed by a region of interest program. Gastric emptying 
time was taken as the time for 50% of the activity to leave the stomach. Oral-small 
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bowel transit was the time for 5% of the activity to enter the small intestine (Fig 3-
1). Small bowel transit was calculated by subtracting the time for 5% of the 
activity to enter the small intestine from the time for first image of terminal ileum. 
Ileocaecum transit time was taken as subtracting the time for first image of 
terminal ileum from the time for definite activity at caecum (Fig 3-2). The 
measurements and their definitions were also summarized in the Table 3-1. 
 
3.2.4 Statistical Analysis 
      All statistical analyses were performed using standard SPSS package (version 
13.0 for windows). Continuous variables were expressed as Mean ± SEM, and 
categorical variables were expressed as frequencies and percentages. To compare 
the differences between IBS and healthy control groups, chi-squared test was used 
for categorical variables and independent samples t-test for continuous variables. 
Non-parametric data were analyzed using the Mann-Whitney U test. Two tailed p 
value less than 0.05 was considered statistically significant. 
 
Table 3-1  Transit measurements and their definitions 
Transit Measurements Definitions 
Gastric emptying half-time The time for 50% of the activity to leave the 
stomach. 
Oral--- beginning of 
terminal ileum 
The time from end of eating radiolabelled 
meal to first image of terminal ileum 
Small bowel transit time The time from 5% of the activity to enter the 
small intestine to  the first image of terminal 
ileum 
Beginning of small bowel  
----caecum 
The time from 5% of the activity to enter the 
small bowel to the definite activity at caecum 
Ileocaecal transit time The time from the first image of terminal 
ileum to the definite activity at caecum 
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Fig 3-2   Normal scan showing transit of ileum to caecum. 
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3.3   Results  
3.3.1 Demographic characteristics of IBS patients and healthy volunteers 
      Thirty non-diarrhea IBS patients with bloating and twelve healthy volunteers 
who met the inclusion and exclusion criteria were recruited for bran scan. Among 
those IBS patients, due to the technical problems, 4 patients’ bran scan data were 
lost. The bran scan data from 26 non-diarrhea IBS patients with bloating and 12 
healthy controls were successfully obtained for analysis. The demographic data 
were summarized in Table 3-2.   
 
       In addition, we randomly chose 12 patients from the 26 IBS patients to be 
matched with those 12 normal controls. Two groups had the same ratio of female: 
male (1:1). In normal control group, there were 6 (50%) Chinese, 5 (41.7%) 
Indian, 1 (8.3%) Malay. In IBS group, there were 7 (58.3%) Chinese, 4 (33.3%) 
Indian and 1(8.3%) Malay. In bloating IBS patients, the mean duration of 
symptom was 2.8 years. No significant differences in prevalence were found in 
terms of age, gender, racial group and weight between these 12 bloating IBS 









Table 3-2 Demographic Data of 26 Bloating IBS patients and 12 Normal Controls 
                                         Normal Controls           Bloating IBS     P value 
                                                 (n=12)                          (n=26) 
Sex [n (%)]                                                                                             0.5 
    Male                                    6 (50)                          10 (38.5) 
    Female                                 6 (50)                          16 (61.5) 
Race [n (%)]                                                                                           0.5 
    Chinese                                6 (50)                           18(69.2) 
     Indian                                  5 (41.7)                        7(26.9) 
     Malay                                  1 (8.3)                          1(3.8) 
Age (Y)                                                                                                  0.07 
     Mean (SEM)                       31.5 (3.0)                    38.5 (2.4) 
Weight (Kg)                                                                                           0.1 
     Mean (SEM)                       61.4(2.7)                      57.6(1.7) 
Duration of Bloating 
Symtom (Y) 




Table 3-3 Demographic Data of 12 Bloating IBS patients with matched normal 
controls 
 
Normal Controls        Bloating IBS         P value 
(n=12)                            (n=12) 
Sex [n (%)]                                                                                                          NS 
    Male                                              6 (50)                            6 (50) 
    Female                                           6 (50)                            6 (50) 
Race [n (%)]                                                                                                        NS 
    Chinese                                         6 (50)                             7(58.3) 
     Indian                                           5 (41.7)                          4(33.3) 
     Malay                                           1 (8.3)                            1(8.3) 
Age (Y)                                                                                                                NS 
     Mean (SEM)                                31.5 (3.0)                      34.8 (2.9)      
Weight(Kg)                                                                                                          NS 
      Mean (SEM)                                61.4(2.7)                       61.5 (2.8)  
Duration of Bloating  
symptom (Y) 




3.3.2 Transit time 
      From the comparison between 26 IBS patients and 12 normal controls, there 
were no significant differences in gastric emptying half-time (152.3±6.8min vs.                  
143.5± 8.8min, P>0.05), beginning of small bowel- caecum time (252.3±
13.2min vs. 234.5±12.6min, P>0.05) and ileocaecal transit time (90.3±10.7min 
vs.103.6±14.9min, P>0.05). Small bowel transit time and Oral-beginning of 
terminal ileum time was significant delayed in 26 bloating IBS patients compared 
with 12 normal controls (155.3±7.9min vs.130.9±9.5 min, P<0.05; 210.6±











































Fig 3-3  Comparison of different transit measurements between 26 bloating IBS 
patients and 12 normal controls. * P<0.05, bloating IBS vs. normal controls 
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         To exclude the possibility that unmatched sample size (26 vs. 12) would 
result in the above significant differences, 12 IBS patients were further randomly 
chosen to do the comparisons with 12 normal controls. Hence, we also describe 
the transit measurements in 12 IBS and 12 controls as below (Demographic data 
was presented in page73, 74). 
Gastric emptying  
      There were no significant differences in gastric emptying half-time between 
12 bloating IBS patients and matched 12 normal controls (155.2±9.2min 
vs.132.8±6.4min, p>0.05) (Fig 3-4). Individual data are shown in Fig.3-5. No 
significant differences were found in gastric emptying half time for those bloating 
relieved by belching (155.4±13.9min, n=6), those bloating not relieved by 
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Fig3-4 Comparison of different transit measurements between matched 12  
bloating IBS patients and 12 normal controls.  





































Normal controls                                    Bloating IBS patients
 
Figure 3-5 Individual gastric emptying half-time (min) in healthy controls and 


















































Figure3-6 Comparison of gastric emptying half-time in IBS patients with bloating 






Small bowel transit 
      Small bowel transit time was significantly longer in bloating IBS patients, 
compared with normal controls group (156.8±10.7min vs. 122.7±9.1, p<0.05) (Fig 
3-4). Individual data are shown in Fig 3-7.  Additionally, bloating IBS patients 
had significant slower oral-beginning of terminal ileum transit time than normal 
controls (221.6±9.8min vs. 178.3±12.0min, p<0.05) (Fig 3-4). 
 
Ileocaecal transit time 
      There were trends that bloating IBS patients had faster ileocaecal transit 
compare to controls, the differences were not significant though. (89.9±11.8 min 













































Figure 3-7 Individual small bowel transit time in 12 normal controls and 12 













































 3.3.3 Bloating symptom and girth measurement 
      During the scan, 91.7% of the patients reported bloating within 60 min after 
the test meal, especially 3 of them reported moderate severe or severe (point 3-4) 
bloating. While none of the normal controls complaint any bloating symptom. The 
peak bloating period appeared in 60-90min after the meal. Bloating score 
decreased gradually after 150min, especially after lunch at 180min (Fig 3-9). 5 
patients experienced bloating in the whole period of scan. Additionally, the 
bloating score during the scan were positively correlated to the small bowel transit 
time in 26 IBS patients (P<0.05, Table 3-4), while no correlation was found 
between bloating score and ileocaecal transit time (P>0.05, Table 3-4).  There 
were no significant changes in abdominal girth from baseline for both IBS and 


















     Fig 3-9    Bloating score in IBS patients during the scan 
                     Data are presented as Mean±SEM    







Table 3-4 Correlation between small bowel\ileocaecal transit and bloating score 
during scan 
 
Small bowel transit  Bloating score       Correlation 
     r                  P 
     155.3±7.9 min      1.0±0.2 0.41             <0.05 
 
ileocaecal transit time Bloating score       Correlation 
     r                  P 
     90.3±10.7 min      1.0±0.2 0.21             >0.05 
            Data are presented as Mean±SEM   . 
 
 
Table 3-5   Girth measurements (cm) in normal controls and bloating IBS patients 
during scan 
 
                           Normal controls         Bloating IBS  patients 
Baseline                  77.2±1.7                       79.1±2.8  
15-60min                 77.3±1.7                       79.3±2.9 
75-120min               77.1±1.7                       79.4±3.1 
135-180min             76.9±1.7                       79.3±3.0 
195-240min             77.7±1.7                       80.0±3.0 
255-300min             77.8±1.7                       80.2±3.0 
315-360min             77.6±1.7                       80.0±3.0 








3.4  Discussion 
The present study has shown the difference of the gastrointestinal transit 
induced by bran and solid meal in IBS patients with bloating and healthy controls, 
using radioscintigraphic method. Our patients were not only met the Rome II 
criteria but also reported non-diarrhea bowel habit with bloating as a major 
complaint. The most striking finding of this study was the significant slower small 
bowel transit of food in the IBS patients with bloating, compared with normal 
controls. Our data appeared to be consistent with the results of a study conducted 
by Cann et al., which found delayed transit both in small intestine and the colon in 
patients who complained of constipation or pain and distension by the breath 
hydrogen test (Cann et al, 1983). 
 
However, it was revealed that rapid small bowel transit of the meal in IBS 
patients with bloating in Hebden et al.’s study, which used similar bran and 
radiolabelled meal method (Hebden et al, 2002). The inconsistency between theirs 
and present study may result from several possible reasons. Firstly, the difference 
may relate to the different race population. Our Asian population presented 
delayed food transit through the small intestine, which support the feature of more 
common with upper abdominal bloating or pain (Chapter 2.3.2). By contrast, most 
western people have lower abdominal bloating or pain (Talley et al, 2001) and less 
upper abdominal complaint. Secondly, it may because Hebden et al used relative 
older healthy controls (median age 41yr, range 21-65yr) compared to patients 
(median age 34.5 yr, range 22-49). In our study, the age was better matched 
between normal controls and IBS patients with bloating (Normal: 31.5±3.0, range 
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21-50yr; patients: 34.8±2.9, range 20-53yr). Thirdly, the possible reason to 
explain the difference was the method of assessment of small bowel transit. We 
analyzed the small bowel transit time from the time for 5% activity to enter the 
small intestine to the time for first arrival of terminal ileum. Moreover, we could 
obtain the transit time of small intestine as well as ileocaecum. While, Hebden et 
al. calculated the small bowel transit time as from the time for gastric 50% 
emptying to the time for 50% of the activity to enter the colon, by which they did 
not particularly clarify the ileocaecal part.  
      
       We further found that the ileocaecal transit in IBS patients with bloating was 
not slower than normal controls, which was different from our initial expectation 
and other studies (Trotman et al, 1986; Phillips et al, 1991). There was even a 
trend of faster ileocaecal transit in bloating IBS patients although without 
significance in our study. Similarly, Hutchinson et al have demonstrated 
significant rapid ileocaecal transit in IBS patients compared to controls 
(Hutchinson et al, 1995). The possible reason could be eating increases ileal flow 
after three to four hours and accelerates transfer from distal ileum to colon (Spiller 
et al, 1986). In this study, our patients were provided with lunch—chicken pie at 
180min. However, it still remains controversial on transit time in ileocaecum 
region. In our study, we integrated the patients’ bloating characteristics with the 
intestine transit times. The results suggested that bloating in our Asian population 
may not originate from ileocaecal transit. Furthermore, it may suggest that small 
intestine dysmotility may possibly correspond to the upper abdominal bloating. 
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        The delayed small bowel transit in IBS patients with bloating is not easy to 
explain, but could because of a disturbance in humoral or nervous controls by the 
small intestine, or could result from a reflex inhibition of small intestinal motility, 
induced by colonic distension (Cann et al, 1983). Moreover, bran is a source of 
non-absorbable fiber, which required more chewing. Particularly, when mixed 
with any meals, it may alter the physical characteristics, the particle size and 
viscosity (Mcintyre et al, 1997). It is possible that such materials stimulate 
hydration to reduce their viscosity during the transition. Hence, it is likely to 
magnify the upper gut motor dysfunction in our IBS patients with bloating.  While 
healthy controls could tolerate it without any symptom. On the other hand, 
impaired small intestinal gas transit in IBS with bloating may also result from 
altered gut motor function (Serra et al, 2001). Likewise, Salvioli et al. 
demonstrated small bowel is the cause of ineffective gas propulsion in bloating 
patients. Indeed, impaired control of gut motility combines with altered sensitivity, 
and both dysfunctions may interact to produce the symptoms in irritable bowel 
syndrome. Minor motility disturbances may become clinically relevant and 
produce symptoms only in the presence of altered gut perception (Azpiroz & 
Malagelada, 2005). 
 
        The correlation between bloating symptom and impaired small bowel transit 
may suggest that the symptoms arise in the small intestine. This is also supported 
by the observation that most of the patients experienced bloating in the first 
several hours of the scan. Although some of patients described that bloating 
symptom often get worsen in the afternoon on the questionnaire, it could be 
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explained by the different meal time on the scan test day. They are given a 
“special big” (bran plus egg sandwich) and even late break fast---9am to 10am. 
Moreover, the scan test was conducted on Saturdays, which means IBS patients 
experienced less life stress and more relax emotion status than normal working 
times. This situation could also result in the bloating symptom and distension on 
scan date was less severe than usual, thus the girth change appeared not so 
significant during the test. In addition, there were less than half of these patients 
(35%) described their bloating as visible distension on the questionnaire. Thus we 
did not find the difference in girth change between IBS patients and normal 
controls during bran scan. And we could not conclude that whether the subjective 
sensation would be corresponded with objective distention of the abdomen from 
the present study.  
 
We noticed that there was no significant difference between the bloating IBS 
patients and normal controls regarding the gastric emptying half-time, which 
suggest that bloating symptom in IBS may not originate from the stomach and 
bran-induced bloating would not affect the gastric emptying. Moreover, it is found 
that the gastric emptying half time of those bloating symptom relieved by belching 
patients had no significant differences from those not relieved by belching patients 
and normal controls. In these bloating IBS patients of our study, those bloating 
relieved by belching may also have Functional Dyspepsia (FD) symptom that co-
existed with IBS. FD exists in about 30% of IBS patients, especially in those with 
constipation-predominant IBS and gastric emptying is delayed in patients with 
concomitant FD but not in those with IBS alone (Stanghellini et al, 2002). 
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However, delayed gastric emptying to solid meal was found in only 23% of 
patients with FD-IBS and 19% of patients FD alone in a 304 subjects involved 
study (Corsetti et al, 2004).  
  
      However, a limitation of the present study was that the colonic transit time 
could not be further obtained, since the isotope used in our study would be not so 
stable after 6 hours. In addition, it would be more exact that the quantity of the 
isotope activity could be used to assess the time of arrival of terminal ileum.  
 
      In summary, the radioscintigraphic method with a bran-containing meal could 
be a useful non-invasive method of assessing the intestine transit in IBS patients. 
As discussed above, we have shown impaired small intestine transit in non-
diarrhea IBS patients with bloating. There are no differences in gastric emptying 
time and ileocaecal transit time in non-diarrhea IBS patients with bloating 
compared with normal controls. In the future, we should further take insights to 
the bloating IBS with diarrhea and bloating symptom alone without IBS 
(functional bloating) by the same method, as to compare with the present study to 

















Chapter 4  
 
 
Effect of 5-HT4 Receptor Agonist 
Tegaserod on Non-Diarrhea IBS 
Patients with Bloating  
-- A Randomized, Double Blind,  









      Irritable bowel syndrome (IBS) is a common condition where patients 
experience a various combination of pain, bloating, and altered bowel habits for 
which there is no organic cause to explain the symptoms. The disease has a 
significant impact on an individual’s quality of life, with profound social and 
economic consequences (Lissner et al, 2001). The diagnosis of IBS is challenging 
because of the lack of histopathological or biochemical marker to characterize the 
disorder. Physicians therefore rely on the symptoms expressed by individual 
patients. The subclassification of IBS patients by their primary symptoms can be 
clinically meaningful in order to select the appropriate treatment (Camilleri & 
Choi, 1997). The underlying mechanisms which contribute to the pathophysiology 
of IBS are currently emerging with the advent of novel therapeutic agents.  
       
      Farthing demonstrated that disturbances in gastrointestinal motility and 
enhanced perception of visceral stimuli (visceral hypersensitivity) both make 
important influence to IBS (Farthing, 1999), which are modulated by input from 
the central nervous system, including the higher centers (Novick et al, 2002). As 
the enteric nervous system plays an major role in regulating these functions, and 
as 5-hydroxytryptamine (5-HT) (Serotonin) is a key enteric neurotransmitter, 5-
HT receptors have been targeted in the development of pharmacological agents for 
the treatment of IBS symptoms (Gershon, 1999). For diarrhea-predominant IBS, 
the 5-HT3 antagonists have been reported to be effective. On the other hand, the 5-
HT4 receptor expressed in the gastrointestinal tract plays a pivotal role in motility. 
The advent of innovative 5-HT4 receptor stimulation can trigger the peristaltic 
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reflex in both animal and human gastrointestinal tract (Grider et al, 1998).  
Furthermore, Schikowski et al. and Coelho et al. have suggested a modulating role 
of 5-HT4 receptors in visceral sensation by studies performed in cats and rats 
(Schikowski et al, 1999; Coelho et al, 2000).  
 
      Tegaserod [3-(5- methoxy- 1H- indol- 3- ylmethylene)- N - pentyl- 
carbazimidamide] hydrogen maleate is a new compound designed as a selective-5-
HT4 receptor partial agonist. Preclinical and clinical investigations have 
demonstrated that tegaserod could stimulate motility throughout the 
gastrointestinal tract. Tegaserod accelerated the gastric emptying of solids in rats 
(Pfannkuche et al, 1995). It is also found tegaserod accelerates gastric emptying 
and gastrointestinal transit in healthy male subjects (Degen et al, 2001). 
 
      A study using scintigraphic method found that tegaserod accelerated orocecal 
transit in IBS patients with constipation (Prather et al, 2000). Morevoer, Novick et 
al have reported that tegaserod produced rapid and sustained improvement of 
symptoms in female IBS patients (Novik et al, 2002).Also, Lissner et al suggested 
tegaserod offered relief of the abdominal pain and constipation associated with 
IBS (Lissner, et al, 2001). Therefore, tegaserod was investigated in the treatment 
of irritable bowel syndrome.  
 
       However, the studies of tegasarod have been largely conducted in Europe and 
the United States. From our previous study (Chapter 3), it is shown delayed small 
intestine transit in IBS patients with bloating in Asian population. In the present 
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study, we hypothesized that tegaserod would accelerate small bowel transit and 
therefore improve the bloating symptoms in IBS patients from Asia.   
 
4.2   Subjects and Methods 
4.2.1 Subjects 
      Thirty IBS non-diarrhea patients predominantly reporting abdominal bloating 
were recruited from University Digestion Centre, NUH. They have satisfied 
inclusion criteria of having the diagnosis of IBS made by experienced 
gastroenterologists (GKA&HKY) based on the Rome II criteria (Thompson et al, 
1999). In addition, their bloating score have to be higher than 1 on a 5-point scale 
(at least have moderate bloating). All patients were symptomatic at the time of 
study. These subjects were asked not to take any medications known to alter 
gastrointestinal and bowel function within a month before and during the study, 
and their history of medications was recorded. Subjects were excluded if they 
were presented with a history of diarrhea (defined as loose or watery stools and /or 
more than three bowel movement per day); if they were pregnant or were breast-
feeding females; if they had organic gastrointestinal, anal, hepatic or other 
systemic disorders; if they had previous gastrointestinal surgery history except 
appendectomy; or if they gave a history of cerebral disease or surgery (See details 
of Inclusion and exclusion criteria in Chapter 2.2.1). Verbal and written consent 
was obtained from each subject. The study protocol was previously approved by 




      The present study used a randomized double blind placebo controlled design. 
Patients who met the inclusion and exclusion criteria were recruited and 
randomized into two groups receiving either Tegaserod (Zelmac; Novartis Pharma 
AG) 6mg b.i.d or an identically appearing placebo for two weeks. Bran scan (See 
details of procedure in Chapter 3.2.2) were conducted just before treatment and at 
the end point of 2 week treatment for each patient. All patients were asked to 
complete Gastrointestinal Symptoms Questionnaire (see Appendix A), Hospital 
Anxiety and Depression scale (HAD) (see Appendix B) and Symptoms Score 
(Appendix C) before and after treatment, for assessment of their gastrointestinal 
/bowel symptoms, psychological status. During the treatment period, subjects 
were asked to complete the bowel diary daily (Appendix D) and record any 
adverse event.  
Gastrointestinal Symptoms Questionnaire  
Detailed symptom assessment with gastrointestinal questionnaire including 
Rome II criteria for the diagnosis of IBS, detailed descriptions of bloating 
complaint such as severity, location, whether relieved with belching or passage of 
stool or flatus, main area of bloating, any known precipitating factors and whether 
there is visible distension. Upper gut symptoms assessment is also included such 
as early satiety, nausea. Bowel Habit assessment is consists of frequency and 
pattern of bowel movement as well as a series related symptoms such as straining, 
feeling of incomplete defecation, etc.  Severity was prescribed as None, Mild, 
Moderate, Severe. “Mild” represents awareness of symptoms, no interference with 
daily activity, can be ignored. “Moderate” means some interference with daily 
activities, can not be ignored, but can continue with work/daily activities. 
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“Severe” represents unable to conduct a range of daily activities, affects 
concentration on work and daily activities.  
Hospital Anxiety and Depression scale (HAD)  
      The HAD consists of a total of 14 items and 2 subscales (anxiety and 
depression) with 7 items each. Answers to each item are given scores of 0-3. The 
scores for each subscale were added to give anxiety scores and depression scores. 
Thus the maximum obtainable score for either anxiety or depression was 21. 
Particularly, score 0-7 means normal, 8-10 represents borderline abnormal, 11-21 
is described as abnormal.  
Symptoms Score  
      Bloating predominant IBS patients and healthy volunteers in our study were 
asked to assess their symptoms (bloating, pain, fullness, belching, nausea, flatus) 
by scores ranging from 0-4 (0 for none, 1 for mild, 2 for moderate, 3 for moderate 
severe, 4 for severe).  
Bowel Diary 
      Bowel diary was recorded daily during 2-week treatment. It consists of stool 
type (based on BSF-Scale), whether or not having “urgent to pass motion”, 
“straining to pass motion”, “feeling of incomplete defecation” and “bloating/ 
pain”.  
 
      All the 30 IBS patients with bloating were offered treatment in a randomized 
parallel double blind placebo controlled manner with tegaserod 6mg b.i.d or 
matching placebo b.i.d. for 2 weeks. Patients, investigator staff, persons 
performing the assessments, and data analysts remain blind to the identity of the 
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treatment from the time of randomization until database lock, using the following 
methods: (1) Randomization data are kept strictly confidential until the time of 
unblinding, and will not be accessible by anyone else involved in the treatment 
study. (2) The identity of the treatments will be concealed by the use of study 
drugs that are all identical in packaging, labeling, schedule of administration and 
appearance, i.e., the tegaserod tablets will be unlabelled and pre-packed in alu-alu 
blisters (10 tabs/blister), and the placebo tablets will match the tegaserod tablets 
and will similarly be unlabelled and pre-packed in alu-alu blisters (10 tabs/blister). 
Unblinding will only occur in the case of patient emergencies and at the 
conclusion of the study. Randomization will be performed using a randomization 
list that is concealed from patients and investigator staff. The list automates the 
random assignment of treatment groups to randomization numbers in the ratio 1:1. 
 
      In Singapore, tegaserod is approved for symptomatic treatment of abdominal 
pain and discomfort, bloating, altered bowel function related to irritable bowel 
syndrome in female patients whose main symptoms are pain/discomfort and 
constipation. This trial will attempt to determine whether tegaserod will improve 
bloating-predominant IBS and gastrointestinal transit. The dose was chosen so as 
not to exceed the recommended and approved maximum daily dose of 
12mg. Allowance will be made to titrate the dose according to patient's response 
and reduced in the event of diarrhoea. 1) Mild diarrhea generally resolves without 
interruption of the study medication and will require no treatment. 2) Moderate 
diarrhea, or persisting mild diarrhea may require a concomitant anti-diarrheal 
agent (e.g. loperamide) or, if diarrhea continues, interruption of study medication. 
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If study medication is interrupted, once the patient has two consecutive episodes 
of formed stool the study medication, at 6 mg b.i.d. can be restarted the following 
day beginning with the morning dose. Interruption of study medication should not 
exceed 4 days. If the patient interrupts study medication for more than 4 days, the 
patient should be discontinued from the study. 3) For severe diarrhea, interruption 
of the study medication may be the first option. Also, if less severe diarrhea fails 
to resolve with the above prescribed treatments, interruption may also be 
necessary. When diarrhea is resolved, study medication (6 mg b.i.d.) should be 
restarted as described above. If bothersome diarrhea reoccurs, study medication 
should be discontinued. The actual treatment of individual patients can be adapted 
as the responsible physician feels is needed. 
 
Bran Scan 
      Bran scan procedure is the same as in the previous study (Chapter 3.2.2). Each 
patient completed twice bran scans—pre-and post- treatment. The method of 
scintigraphic analysis is also the same as in the previous study (Chapter 3.2.3). 
 
4.2.3 Statistical Analysis 
      All statistical analyses were performed using standard SPSS package (version 
13.0 for windows). Continuous variables were expressed as arithmetic mean ± 
SEM, and categorical variables were expressed as frequencies and percentages. To 
compare the differences between tegaserod and placebo groups, chi-squared test 
was used for categorical variables and independent samples t-test for continuous 
variables. Paired t-test was used to compare the differences in treatment groups 
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4.3.1 Demographic characteristics  
      A total of 30 IBS patients with bloating were recruited and randomly assigned 
to receive either Tegaserod or placebo (6mg twice daily). All the patients 
completed the 2 weeks’ study. There was one patient reported moderate diarrhea 
in the first 4 days. However, he felt comfortable with that and completed the study. 
There were no clinically significant differences between the treatment groups for 
any of the key demographic features (Table 4-1). The largest racial group was 
Chinese. The ratio of female to male and duration of IBS were similar in both 
groups. Additionally, there were no important differences between treatment 
groups with respect to the severity of bloating symptom, bowel habit and 









Table 4-1 Demographic data of treatment groups 
                                   Tegaserod (n=15)            Placebo (n=15)                  P value 
Age [Mean±SEM]          38.3±3.1                          39.0±3.4                           NS 
Sex[n(%)]                                                                                                         NS 
     Female                       10 (66.7%)                        9 (60%)                                   
     Male                            5 (33.3%)                         6 (40%)                             
Race[n(%)]                                                                                                       NS 
     Chinese                      12 (80%)                          10 (66.6%) 
     Indian                          2 (13.3%)                          4 (16.7%) 
     Malay                          1 (6.7%)                            1 (6.7%)    
Weight (kg, Mean±sem)  58.6±3.6                           55.7±3.3                         NS 
Duration of symptom 
(year,mean±sem)               3.1±0.7                             3.3±0.5                          NS 
 
 
4.3.2 Symptoms characteristics in treatment groups 
Overall satisfactory relief 
      Tegaserod caused significant improvement in satisfactory relief of IBS 
symptoms at the end point. After 2-week treatment, the proportions of patients 
with satisfactory relief were 80% for Tegaserod and 40% for placebo (p<0.001) 
(Fig 4-1). In placebo group, there was even a patient complaint “very dissatisfied” 
with the treatment.  
 
Symptom score 
       The total symptoms score was significantly decreased in tegaserod group after 
2-week treatment (4.4±0.8), compared with placebo group (2.5±0.5, P<0.05). The 
total symptoms score after treatment was also significant lower in tegaserod group 
than that in placebo group (5.0±0.6vs.7.6±0.9, P<0.05). The baseline scores were 
similar between two groups. Particularly, the bloating score and fullness score was 
significantly decreased after treatment in tegaserod group compared with placebo 
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group. Other sub-scores (pain, belching, flatus and nausea) were not significantly 
changed after tegaserod/placebo treatment (Fig 4-2). 
 
Effect on bloating 
       The proportion of moderate and severe bloating decreased greatly in 
tegaserod group after treatment (Table 4-2). Most of the patients (66.7%) had mild 
bloating after tegaserod treatment whereas all of them (100%) had at least 
moderate bloating at baseline. While in placebo groups, 60% of the patients still 
felt bloating after treatment. The baseline bloating symptom was similar between 
two groups.  
 
From patients’ diary, during the two week treatment, the bloating days in 
tegaserod and placebo groups were 6.8±0.4 days vs. 9.7± 0.7 days (P<0.01). 
However, there were no significant differences between tegaserod and placebo 
group in the days of “pain”, “strain to pass motion”, “incomplete defecation” and 
“urgent to pass motion” (Fig 4-3). 
 
Effect on bowel habits 
       There was a tendency towards improvement in bowel symptoms by tegaserod 
(P value for “constipation” is 0.1’; “<3 bowel movements/day” 0.1; “incomplete 
defecation” 0.09). Only 13.3% of the patients reported less than 3 times bowel 
movement per day and 13.3% had more than 3 times per day after tegaserod 
treatment, whereas 46.6% patients still reported less than 3 times bowel 
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movement per day and no patients experienced more than 3 times per day in 
placebo group. From the bowel diary, the tegaserod group (4.6±0.2) had 
significant higher stool type (base on BSF-Scale) during the second week of 
treatment, compared with placebo group (2.7±0.5, P<0.05).  However, there were 
little changes in incomplete defecation, urgency defecation and strain defecation 
throughout the study in tegaserod and placebo groups (See Table 4-2 based on 
Gastrointestinal Symptoms Questionnaire, Fig 4-3 based on Bowel Diary). 
. 
Psychological parameters (HAD Score) 
      The changes in the total anxiety, total depression scores after treatment among 
the tegaserod group were similar to those of the placebo group. No significant 
differences were found in anxiety and depression scores for baseline and after 
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       Fig 4-1   Percentage of satisfactory relief in the tegaserod and placebo groups  































Fig4-2 Symptoms Scores before and after treatment between the 
tegaserod/placebo groups. * P<0.05 after tegaserod vs. before tegaserod treatment; 






Table 4-2 Symptoms characteristics before and after 2-week treatment 
                                                   Tegaserod                                 Placebo 
    
                                        Baseline  After treatment        Baseline     After treatment 
Severity of bloating  
 [n (%)] 
       Mild                           0 (0%)      10 (66.7%)             0 (0%)                6(40%) 
Moderate+ Severe        15(100%)      5 (33.3%)*            15 (100%)           9(60%) 
                                           
 
Bowel Habits 
    Constipation              7 (46.6%)       3 (20%)                6 (40%)             5 (33.3%) 
<3 bowel movements/d  5 (33.3%)       2(13.3%)             6 (40%)            7 (46.6%) 
>21 bowel movements/w  0 (0%)        2 (13.3%)              0 (0%)              0 (0%) 
Strain to pass motion       7 (46.6%)    3 (20%)               10 (66.7%)         8 (53.3%) 
Incomplete defecation   13 (86.7%)     9 (60%)              15 (100%)        10 (66.7%) 
Urgent to pass motion    6 (40%)        7 (46.6%)               6 (40%)            6 (40%)  
Hard stool form  
          Mild                  5 (33.3%)         7(46.6%)               4(26.7%)           7(46.6%) 
          Moderate          7 (46.6%)          5(33.3%)              7(46.6%)            6(40%) 
          Severe              0 (0%)               0 (0%)                   1 (6.7%)            1 (6.7%)    
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Fig 4-3   Number of symptoms days in tegaserod\placebo group during 2-week 






Table4-3 Comparison of HAD score between baseline and after treatment 
                                                 Baseline                                     Decrease in scores 
 
                                 Tegaserod          Placebo                Tegaserod              Placebo 
Anxiety Score           8.0±1.1             7.3±0.9                   0.4±0.2                 0.8±0.6 
Depression Score       6.5±1.8            3.4±0.9                   0.3±0.5                 0.2±0.1 










4.3.3 Transit measurements 
      Among 30 IBS patients with bloating, due to the technical problems, 4 
patients’ bran scan data were lost (2 in tegaserod group, 2 in placebo group). 
There were some confused scan data in 2 of tegaserod group and 1 of placebo 
group (from nuclear medicine department data analysis report). 2 patients in 
placebo group and 1 patient in tegaserod group could not repeat bran scan just 
after 2 week treatment. Finally we got 10 patients in each group for analysis. 
Gastric emptying  
      Gastric emptying half time was not significantly altered by tegaserod 
(141.5±6.3min vs. 144.3±6.6min, P=NS) and placebo as well (161.8±12.9 min vs. 
150.8±11.4min, P=NS). (See Fig 4-4) 
Small bowel transit  
      Tegaserod had a statistically significant effect on the small bowel transit time 
compared with placebo (Fig 4-4). Times were significantly shorten by tegaserod 
compared with placebo (p<0.01, based on changes). Fig 4-5 shows the individual 
changes between baseline and after treatment in tegaserod and placebo groups.  In 
addition, small bowel transit time after tegaserod treatment was significantly 
faster than baseline (127.2±6.5min vs. 149.5±12.7min, p<0.05) and placebo group 
after treatment (159.1±13.1min, P<0.05).  
Ileocaecal transit  
      The ileocaecal transit times were not significantly changed by tegaserod and 
placebo. The ileocaecal time was 82.1±8.5 min for tegaserod vs.95.7±12.1min for 






































Before Tegaserod treatment 
After Tegaserod treatment
Before Placebo treatment 
After Placebo treatment *
 
# 
Fig 4-4 Transit measurements before and after treatment between the 
tegaserod/placebo groups. * P<0.05, after tegaserod vs. before tegaserod treatment; 
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Fig 4-5  Individual data showing the changes in small bowel transit between 
baseline and after treatment with tegaserod and placebo. P<0.01 tegaserod vs. 






Bloating perception during bran scan 
 
      As shown in Fig 4-6, bloating perception during bran scan was lower after 
tegaserod treatment, especially at 60, 75, 240, 255 min. While there were no 
significant changes in placebo group. After treatment, the tegaserod group had 
greater decrease in bloating score at every 15 minutes over the entire scan period, 
compared with placebo group (p=0.001, using General Linear Model (GLM) 
analysis). 
Changes in bloating/pain score and small bowel transit times 
      After tegaserod treatment, the decrease in bloating score was positively 
correlated to the decrease in small bowel transit times (r=0.66, P<0.05). However, 
no correlation was found in placebo group (Table 4-4a).There were no 
correlation between changes in pain score and in small bowel transit times (Table 
4-4b). 
Effect on patients with visible bloating  
       The IBS patients with visible distension had significant shorter small bowel 
transit time after tegaserod treatment, compared with those with visible 
distension after placebo treatment (133.8±8.8 vs.175.3±13.1min, P=0.04). There 
were significant differences in changes of small bowel transit time in visible 
distension patients between tegaserod and placebo groups after treatment (-
18.1±11.8vs. 20.9±8.9 min, P=0.03. “-”denotes decrease). The baseline small 
bowel transit times were similar between two groups.  There was a tendency on 








Table 4-4a Correlation between changes in small bowel transit and changes in 
bloating score after treatment 
 
                      Changes in Small             Changes in                  Correlation 
                       bowel transit (min)          bloating scores             r              P          
Tegaserod           -22.3±9.8                    -1.2±0.2                     0.66        <0.05 
 
Placebo                 17.9±5.8                    -0.9±0.7                    -1.30        >0.05 




Table 4-4b Correlation between changes in small bowel transit and changes in 
pain score after treatment 
 
                      Changes in Small             Changes in                  Correlation 
                       bowel transit (min)          pain scores                   r              P          
Tegaserod           -22.3±9.8                    -0.4±0.2                     0.46        >0.05 
 
Placebo                 17.9±5.8                    -0.4±0.3                    -0.28        >0.05 
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Fig 4-6 Bloating score during bran scan before treatment and after treatment in 
tegaserod and placebo group. Data are presented as Mean+SEM. *P<0.05, before 
tegaserod treatment vs. after tegaserod treatment.  






      The present study evaluated the effects of the selective 5-HT4 receptor 
partial agonist--tegaserod, on the symptoms and the gastrointestinal transit of 
irritable bowel syndrome patients with predominant bloating. This study is a 
randomized, double blind and controlled study of IBS conducted in Asian 
population. Non-diarrhea IBS patients with bloating were recruited according to 
Rome II criteria. The results showed the therapeutic advantage of tegaserod in 
this patient population. Compared with placebo, administration of oral tegaserod 
6mg twice a day for two weeks significantly alleviated bloating. This is 
consistent with the study conducted in European IBS population with abdominal 
pain, bloating, and constipation (Muller et al, 2001). Furthermore, in a US 
population, tegaserod produced a statistically significantly greater response rate 
than placebo at the end-point in female IBS with constipation (Novick et al, 
2002). 
 
        It was observed that 80% of the patients achieved satisfactory relief from 
the symptoms and significant decreased in bloating symptom score but not in 
other symptom score (such as pain, belching and flatus) during the 2 week 
tegaserod treatment. This demonstrated a relative rapid onset of action of 
tegaserod. Moreover, 66.7% of these patients with at least moderate bloating had 
mild bloating after tegaserod treatment. While 60% patients remained to 
experience moderate or severe bloating in placebo group. Meanwhile, the 
bloating score was significant lower after tegaserod treatment. Furthermore, from 
the bowel diary, the days of bloating symptom in tegaserod group were 
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significant less than that in placebo group. There were no such differences in 
pain symptom. These findings may suggest that improvement of symptom is 
mainly in bloating after tegaserod treatment in the present study.  
 
It was also found that tegaserod could improve the stool frequency and stool 
forms. However, there were little changes in urgent defecation, incomplete pass 
motion strain defecation throughout the study in both groups. One possible 
reason would be the most bothersome complaint of these IBS patients was 
bloating, which means that they may focus more on the bloating improvement 
than the changes of other symptoms during the treatment. Further explanation 
would relate to the limited period (2 week) of the treatment in our study.  
 
        A relatively high percentage of patients felt satisfied for placebo in the 
present study. This is partially due to the variability of the severity of the 
symptoms, or may reflect the natural progression of a disease that can fluctuate 
in severity over time or influence of other factors such as psychological influence 
on perceptions of relief (Muller et al, 2001; Kellow et al, 2003). In addition, it 
also could be explained by the fact that IBS is a heterogeneous disorder. As 
demonstrated by Thompson in a review of the placebo response, the time course 
of the placebo effect in a chronic “static” disorder, such as hypertension, may 
differ from that in a chronic fluctuating disorder, such as irritable bowel 
syndrome, in which some patients undergo spontaneous improvement of their 
condition (Thompson, 2000). 
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       In the present study, we found no significant differences in anxiety, 
depression scores between the tegaserod and placebo groups from baseline to the 
end of two-week treatment. It seems likely to suggest that beneficial effects of 
tegaserod on IBS patients may be independent of its action on or not associated 
with patients’ psychological profile. However, we could not exclude the 
possibility that Hospital Anxiety & Depression Scale, which was used in the 
current study, might not be sufficiently sensitive to detect minor changes in the 
psychological status. Or, the two-week treatment may not be long enough to 
cause the detectable psychological alterations.  
 
        Visceral hypersensitivity is among the most important underlying 
mechanisms of IBS. In animal studies investigating the effect of tegaserod on 
visceral sensitivity, it reduced the firing rate in spinal rectal afferent nerves in the 
cat (Schikowski et al, 1999), and increased the pain threshold on colorectal 
distension in rats (Coelho et al, 2000). Thus, the role of tegaserod in modulating 
visceral perception might partially explain the observation in the present study 
that significant improvement in bloating compared with placebo.  
 
         On the other hand, our previous study has demonstrated impaired small 
intestine in Asia IBS patients with bloating (Chapter 3). Clearly, current results 
showed tegaserod, 6mg daily, accelerates small bowel transit without any effect 
on gastric emptying and ileocaecal transit, which was associated with significant 
relief of bloating symptom in tegaserod over placebo. It is in agreement with a 
previous study reported by Prather et al, which revealed that oral tegaserod 2mg 
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b.i.d for one week accelerated small intestinal transit in a randomized, double 
blind, placebo controlled study in patients with constipation-predominant IBS 
(Prather et al, 2000). In addition, we further found that the improvement of 
bloating score was positively correlated to the decrease of small bowel transit 
time, whereas no such correlation were shown between changes in pain score 
and small bowel transit.  
 
However, it is observed in Degen’s study that tegaserod not only speeded 
up the small bowel transit, but also shortened the gastric emptying and colonic 
transit times. The difference between the results of Degen et al and those 
obtained in the current study, might because they investigated the healthy 
subjects in Europe whereas the current study focused on the IBS patients with 
bloating in Asia. Moreover, they took the oral as well as intravenous 
administration of tegaserod while in the present study only oral administration 6 
mg b.i.d was given.  
 
On the other hand, at current stage, we could not conclude the effect of the 
tegaserod on colonic transit since the procedure stopped at the food arrival at 
ascending colon or maximum six hours. Hence, the lack of any effect of 
tegaserod on gastric emptying and ileocecal transit time in the present study 
suggests that the potent effect is predominantly on small intestine transit. 
Furthermore, we found that the decrease in the small bowel transit time was 
positively correlated to the improvement in bloating score after tegaserod 
treatment.  
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There may be a significant pharmacodynamic advantage of tegaserod, since 
none of the current agents is particularly effective in stimulating small bowel 
motility (Degen et al, 2001). Although the effects on human small intestine 
motor activity in vivo are unknown, the stimulatory effect of tegaserod on 
intestinal motor function is thought to be mediated by the activation of 5-HT4 
receptors. Thorough preclinical investigation has revealed that tegaserod 
stimulates the release of specific neurotransmitters, such as calcitonin gene-
related peptide, substance P and vasoactive intestinal peptide, from human 
jejunal segments and stimulates peristaltic reflexes in vitro (Grider et al, 1998).  
 
  In conclusion, tegaserod, 5-HT4 agonist, at a dose of 6mg twice daily in 2 
week course accelerates small bowel transit without changes in gastric emptying 
and ileocaecal transit in IBS patients with bloating in Asian population. Such 
effect is associated with effective relief of bloating symptom and partial 
improvement in bowel habits. In addition, the improvement of bloating score is 
positively correlated to the decrease of small bowel transit time. Tegaserod could 
provide effective treatment for non-diarrhea IBS patients with bloating.  
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Gastrointestinal Symptoms Questionnaire 
 
• “Often” refers to a frequency of at least 25% of the time 
• “Severity” of symptoms refers to the severity of at least 50% of episodes 
• 0 = None 
• 1 = Mild (awareness of symptoms, no interference with daily activities, 
can be ignored) 
• 2 = Moderate (some interference with daily activities, cannot be ignored, 
but can continue with work/daily activities) 
• 3 = Severe ( disabling, unable to conduct a range of daily activities, affects 
concentration on work and daily activities) 
 
Upper GUT Symptoms 
 




























 Severe  
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7.  Did your stomach often become over-filled soon after starting to eat, out of 


























11. Where do you usually feel the pain? 


























When you have the pain, are your bowel movements often: 
 
























22. Where do you usually feel the bloating? 
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When you have the bloating, are your bowel movements often: 
 

















31. When is your bloating worse? 




 At night 
 
32. Are there any known precipitating factors for the bloating? 
 Yes  please specify : _____________________________ 
 No 
 













 Alternating constipation/diarrhoea 
 
 
Did you often have bowel movements: 
 








With regard to your stools, were they often: 
 





















41. After finishing a bowel movement, did you often feel there was still stool that 






42. Did you often experience an urgent need to open your bowels that made you 

























Appendix B  
 
Hospital Anxiety and Depression (HAD) Scale 
 
1) Doctors are aware that emotions play an important part in most illnesses.  
This questionnaire is designed to help your doctor to know how you are 
feeling. 
2) Please read each item, then place a tick ( ) in the box which comes closest 
to how you have been feeling during the past week. 
3) Don’t take too long over your replies; your immediate reaction to each 




  I feel tense or wound up:  
 □  3  Most of the time      
 □  2  A lot of the time                
 □  1  Time to time 
 □  0  Not at all 
*I feel as if I am slowed down:  
 □  3  Nearly all the time  
 □  2  Very often  
 □  1  Sometimes  
 □  0  Not at all 
*I still enjoy the things I used to enjoy: 
 □  0  Definitely as much  
 □  1  Not quite so much  
 □  2  Only a little  
 □  3  Hardly at all 
I get a sort of frightened feeling like 
butterflies in the stomach:  
 □  0  Not at all  
 □  1  Occasionally  
 □  2  Quite often  
 □  3  Very often 
I get a sort of frightened feeling as if 
something awful is about to happen:  
 □  3  Very definitely and quite badly  
 □  2  Yes, but not too badly  
 □  1  A little, but it does not worry me  
 □  0  Not at all 
*I have lost interest in my 
appearance:  
 □  3  Definitely  
 □  2  I do not take so much care as I 
             should  
 □  1  I may not take quite as much 
care  
 □  0  I take just as much care as 
ever 
*I can laugh and see the funny side of 
things:  
 □  0  As much as I always could  
 □  1  Not quite as much now  
 □  2  Definitely not so much now  
 □  3  Not at all 
I feel restless as if I have to be on 
the move:  
 □  3  Very much indeed  
 □  2  Quite a lot  
 □  1  Not very much  
 □  0  Not at all 
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Worrying thoughts go through my 
mind:  
 □  3  A great deal of the time  
 □  2  A lot of the time  
 □  1  From time to time but not too 
often  
 □  0  Only occasionally 
*I look forward with enjoyment to 
things:  
 □  0  As much as ever I did  
 □  1  Rather less than I used to  
 □  2  Definitely less than I used to  
 □  3  Hardly at all 
*I feel cheerful:  
□  3  Not at all  
□  2  Not often  
□  1  Sometimes  
□  0  Most of the time 
I get sudden feelings of panic:  
 □  3  Very often indeed  
 □  2  Quite often  
 □  1  Not very often  
 □  0  Not at all 
I can sit at ease and feel relaxed:  
 □  0  Definitely  
 □  1  Usually  
 □  2  Not often  
 □  3  Not at all 
*I can enjoy a good book or radio 
or TV programmer:  
 □  0  Often  
 □  1  Sometimes  
 □  2  Not often  
 □  3  Very seldom 
 
 
Scoring: Even questions (with*) are for depression. Odd questions are for anxiety. 


















For the symptoms which you experience at least 3 days per week, please choose 





Symptom score (Likert scale)  
0 = none 1 = mild 2 =  
moderate
3 =  
moderate 
severe 
4 = severe 
abdominal pain      
abdominal fullness      
bloating      
belching      
nausea      
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